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ABSTRACT 
Localized Surface Functionalization with Atmospheric-Pressure 
Microplasma Jet for Cell-on-a-chip Applications 
Chengyang Wang 
Wei Sun, Ph.D. 
 
Surface properties of biopolymers are crucial for providing topographical 
and chemical cues to affect cellular behaviors, such as attachment, spreading, 
viability, proliferation, and differentiation. As an effective surface modification 
technique, plasma treatment is often applied to enhance surface wettability, 
adhesion, and biocompatibility of polymers. This study concentrates on developing 
technical platforms, experimental procedures, and computational-statistical models 
to manipulate and control the cellular functions on specifically modified polymer 
surfaces. A novel freeform microplasma-generated maskless surface patterning 
process was developed to create spatially defined topological and chemical features 
on biopolymer surface. Global and localized plasma functionalization was 
performed on polycaprolactone (PCL) samples to introduce biophysical, 
biochemical, biological and structural cues to enhance cellular response including 
attachment, proliferation and differentiation. A plasma computational-statistical 
model was developed to predict the changes in biopolymer surface 
physicochemical properties following the oxygen based plasma surface 
functionalization. Furthermore, an integrated system including localized plasma 
functionalization was specifically designed for the development of biologically 
inspired devices. The capabilities, benefits, and challenges of the integrated 
multifunctional biofabrication system to develop cell-on-a-chip device were also 
xiv 
 
 
illustrated. The objective of this thesis is to contribute scientific and engineering 
knowledge to the utilization of plasma chemistry to enhance surface 
functionalization, development of an engineering model for local plasma treatment, 
and integration of biofabrication processes to assemble cell-on-a-chip devices. 
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CHAPTER 1: INTRODUCTION 
Part of this work first appeared in [1] and was done in collaboration with Zhenyu 
Tang, Yu Zhao, Rui Yao, Lingsong Li, and Wei Sun. 
1.1 Surface Modification for Fabrication of 3D Cell Model 
The US Food and Drug Administration (FDA) has reported that there is a 
high percentage (92%) of new drug candidates failing between the pre-clinical and 
clinical development phases [2]. Animals like the Wistar lab rats are candidates 
utilized in conventional drug investigations. The results from these rats are 
analyzed warily since rodents’ metabolism behaviors to drugs are considerably 
different compared to human beings. An in vitro cell model (human cells) has the 
potential to be a drug testing platform to investigate absorption, distribution, 
metabolism, elimination, and toxicity. For example, Shuler et al., developed a 
microscale in vitro system that simulates a human surrogate for drug analysis in 
which different organs are united in sequence by channels with a fluid circuit inside 
[3]. Powers et al. conceived a micro-fabricated array bioreactor for a perfused 3D 
liver culture. This has been used to simulate the in vivo environment at certain 
perfusate flow rates and studies fluid shear stresses. After being cultured for two 
weeks within the etched channels, the primary (rat) liver cells relocated themselves 
and then began to form tissue-like structures [4]. This methodology is used to 
simulate the efficacy of drugs in vivo.  
 
2D monolayer was once widely utilized as a useful in vitro model because 
of its feasibility to set up with a relatively good viability in culture. However, 2D 
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monolayers lack structural architecture. Due to the non-physiological environment, 
cells become distinct from the original human tissue. E.g. Bissell reported that 
normal epithelial cells grown in monolayers are highly plastic and show many 
characteristics as tumor cells [5]. Pampaloni et al. found that primary hepatocytes 
cultured in 2D environment become undifferentiated after several passages and lose 
particular functions as synthesis of drug metabolizing enzymes, which are crucial 
to drug testing [6]. A 3D cell model is a conclusively better platform to simulate a 
substitute to real tissue. An advantage of 3D cell models, is their regulated 
microenvironment that mimics geometrical, chemical, and mechanical aspects of 
real tissues. Moreover, a 3D cell model can be enabled to mimic cell morphology 
and its environment directly, which can determine the both external cell behavior 
and internal gene expression [7]. E.g. Mostov et al. showed functional spheres with 
similar spherical shape, compared to a real tissue that was produced by culturing 
Mardin-Darby Canine Kidney (MDCK) cells in 3D collagen, while, only 
undifferentiated monolayers were generated by MDCK cells in 2D generate [8]. 
Another advantage of 3D cell models is that it can eliminate ethical issues based on 
animal testing. Various kinds of techniques and devices with the idea of building 
3D cell model have been developed, such as; cell culture in 3D hydrogels, cellular 
spheroids, cultures on microstructured materials, cell-on-a-chip devices, etc. 
(Figure 1) [9]. 
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Cell-substrate interaction is critical to affect the validity of any cell model. 
Physical, chemical, and biological modifications of a substrate’s surface impacts 
the quality of cell-substrate interaction in any cell platform. Studies with different 
cells and polymers have indicated that cellular functions are predictable and 
controllable through proper surface modifications. Wang et al. have showed that 
positively charged functional groups incorporated in poly(D,L-lactide) (PDLLA) 
surface could enhance the interaction between the PDLLA surface and the 
negatively charged cells [10]. Lee et al. discovered that the existence of an aromatic 
 
Figure 1. Examples of 3D cell models fabricated with various techniques [9]. 
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ring close to the ionizable group in sodium p-styrene sulphonate (NaSS) attracts 
more cells onto the plasma surface [11]. Yildirim et al. proved that the increased 
surface roughness on the biomaterial surface increases the cellular attachment and 
proliferation [12]. It can be concluded that physicochemical and biological 
properties of a substrate’s surface directly controls critical cellular functions, 
including but not limited to, attachment, migration, proliferation, differentiation, 
and apoptosis. Biomaterial functionalization techniques allow physicochemical and 
biological properties of a biopolymer to be adapted to mimic an in vivo 
microenvironments for cells on an in vitro platform, such as a cell-on-a-chip device. 
 
1.2 Plasma Surface Functionalization 
Plasma surface modification has been constantly developed to functionalize 
many biomedical instruments and devices wholly or partly made from biomaterials, 
including but not limited to, bioactive scaffolds, artificial heart valves, vascular 
grafts, catheters, stents, membranes for hemodialysis, filters for blood cell 
separation, and prosthetic devices [13]. There many unique benefits of using plasma 
treatment for surface modification, compared to other physical, chemical, and 
photochemical modification techniques. Firstly, the unit of thickness on a plasma-
modified surface ranges from ångström to nanometer [14]. Therefore, it is possible 
to modify the target material’s surface uniformly without changing the bulk 
properties of the material using plasma treatment. Secondly, plasma treatment can 
avoid the challenges encountered in wet chemical techniques such as residual 
solvent on the surface, as well as swelling of the substrate [15]. Thirdly, low 
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temperature and high temperature plasma can be applied to either minimize heat 
damages or initial drastic reactions respectively, depending on different treating 
purposes [16].  
 
Free charge carriers in an electrically neutral plasma permit conductivity, 
which depends on several parameters including the number, the mass, and the 
collision frequency of the charge carrier, as well as the electron charge. Therefore, 
it is feasible to control the surface physical properties and chemical functional 
species on a biopolymer by selecting feeding gases with different chemical 
elements and compounds. Common feeding gas includes argon, helium, nitrogen, 
oxygen, fluorine, carbon dioxide, etc. Oxygen-based plasma discharge is often used 
to modify and functionalize the surface of a biopolymer by introducing oxygen 
functional groups including hydroxyl (-C-OH), carbonyl (-C=O), carboxyl (-OH-
C=O) groups, further to improve cell attachment and promote cellular functions. 
[17]. 
 
1.3 Engineering Models of Plasma Process 
Industrial plasma sources have been developed and researched for a long 
time, but understanding the fundamental processes for an application like plasma 
treatment, is generally guided by repetitive testing instead of analytical or 
computational modeling. Modeling of plasma gas discharges provides researchers 
with a cost-effective tool to investigate plasma formation mechanisms as well as 
optimization of process parameters for targeted treatment. As early as 2000, Held 
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published an analytical model of a dielectric barrier discharge (DBD) cylindrical 
ozonizer to investigate the optimized ozone concentration as functions of the 
ozonizer geometry, the electric power, the fluid flow, the temperature and the 
pressure [18]. Later, Castellanos et al. developed an axial symmetrical plasma 
chemical and electrical model of a wire-to-cylinder corona discharge to predict 
ozone concentration [19]. Such developments in this ozone modeling field 
contribute to the knowledge base of plasma discharge, and eventually lead to the 
modeling of atmospheric-pressure discharges. 
 
Modeling of atmospheric-pressure discharges depends on several elements: the 
physical processes, the range of time scales, and the spatial scales. Many models 
focus either on the discharge formation mechanisms at atmospheric pressure, or on 
chemical change inside discharge as well as on surfaces. For example, Golubovskii 
et al. performed numerical calculations of spatio-temporal characteristics, such as 
the amplitude and frequency of the applied voltage, discharge gap width, and 
thickness of dielectric barriers by using a one-dimensional fluid model for 
homogeneous barrier discharge in helium [20]. Yurgelenas and Wagner composed 
a two-dimensional computational model of dielectric barrier charge for short gaps 
(1-2 mm) in air to find residual surface charge distribution [21]. A detailed global 
model of Helium and Water plasmas was reported by Kong et al. to verify Penning 
processes as the main ionization mechanism [22]. Gas heating was included to 
shape electric field profiles in a numerical simulation of a DC microplasma 
discharge in Helium, developed by Donnelly et al. [23]. Much relevant to the topic 
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of this thesis, He and Zhang explored a one-dimensional radio-frequency fluid 
plasma model of Helium and Oxygen, to study generation of reactive oxygen 
species [24]. As mentioned previously, modeling of atmospheric-plasma sources 
often includes tracing physical processes such as discharge breakdown, fluid 
dynamics, radical chemistry and surface kinetics occurring over vastly different 
scales in space and time [25]. 
 
1.4 Fabrication of in vitro Cancer Models 
According to recent reports, cancer(s) in human is becoming a leading cause 
of death worldwide. This accounts for 7.9 million deaths in 2007, and 12 million 
deaths in 2030 as estimated [26]. The lack of a thorough understanding of cancer 
biology is currently a key barrier to investigate the formation, to recognize the 
invasion, and to track metastasis of malignant tumor [27]. Although much effort 
has been carried on to cancer-related studies, the long duration of cancer 
development restricts the feasibility and reproducibility of cancer studies in situ 
[28]. There is an urgent need for in vitro cancer models that are sufficient and 
efficient in mimicking the microenvironment where the cancerous cells reside and 
the tumor develops. Such in vitro cancer models have been proved effective in 
studying cancer pathogenesis, anti-cancer mechanism and drug testing [29]–[31], 
as well as in studying cancer development for bladder [30]–[34], breast [5], [35]–
[46], kidney [6], [47]–[49], lung [50]–[57], ovarian [58]–[66], pancreatic [67]–[70], 
and prostate [71]–[82]. On the mechanism side, the use of  a 3D cancer model(s) 
along with microarray technologies could accelerate study on different causes and 
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modes of cancer cell motility in the metastasis process, as 3D environment 
resembles in vivo situation of cancer cell invasion [83]. Possible mechanism of cell 
death could also be revealed in an in vitro model, particularly to identify the way a 
cell alters its apoptotic behavior when reacting to exogenous stimuli from matrix 
microenvironment of surrounding tissue architecture [84]. On the application side, 
a microscale in vitro physiological model was applied to discover cell-drug 
interactions, to evaluate target organ toxicity arising from exposure to drugs or 
other external agents, and to study cancer metastasis in disease model [85]. 
Additionally, application(s) of a cancer model system(s) in biology may help to 
reduce the use of animal models in many research laboratories and pharmaceutical 
companies for various drug toxicity testing. A few research groups have noticed 
and traced the trend of 3D in vitro models, from an engineering view [86], [87], an 
oncology perspective [88], [89], or a mixed approach [90], [91]. These reviews 
covered different aspects of a 3D cancer model system, such as cell and biomaterial 
selection [86], [92], culture method selection [87], microenvironment and 
morphogenesis in 3D model [89], the role of tissue engineering in cancer modeling 
[90], [91]. This chapter focuses on these reports and discuss some recent 
developments on a novel 3D in vitro cancer model used in cancer studies, along 
with the modeling design and fabrication techniques and the potential applications 
to biology, pathogenesis study and drug testing.  
 
Survey on open literatures have shown that most cancer and tumor 
biological studies are based on two-dimensional (2D) cell models (i.e., 2D 
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monolayer cell models cultured on tissue culture plates). Traditional 2D biology 
studies have been proven effective in a certain degree for explaining cancerous cell 
behaviors and interpreting hypotheses of possible mechanisms. However, the 
interactions between cells-cells and cells-extracellular matrices in true 
physiological tissues are difficult to be mimicked by 2D models due to 
insufficiency on structural, mechanical and biochemical cues. For example, the 
limit of 2D breast cancer model was that its 2D flat monolayer culture was unable 
to provide mammary gland stroma, which accounts for over 80% volume of the 
resting breast volume [93]. In most cases, cells in 3D environment are able to 
expose to other cells or extracellular matrices, but in 2D model are often limited to 
expose to fluid, intermediate and flat culture substrate.  
 
Biological studies suggest that cells in a 3D modeling environment may 
have different behaviors, including cell function [32], differentiation [6], drug 
metabolism [64], gene expression and protein synthesis [94], morphology [95], 
proliferation [96], and viability [95].. Early in 1994, Boxberger and Mayer reported 
that 3D multicellular spheroids induced favorable cell-cell contacts, organized cell 
pattern, a distinct endoplasmic reticulum, and a marked Golgi apparatus in human 
bladder carcinoma cell line RT112 cells [32]. At that time the studies focused on 
feasibility of 3D cell culture, and effects of growth factors on it [97], [98]. With the 
development of advanced techniques in cell culture and microfabrication field, 
more results in favor of 3D models were reported. In a comparison study of 3D 
spheroids vs. monolayers of human hepatoma cell line HepG2, 3D culture not only 
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increased cellular organization and cell-cell adhesions but also decreased cell 
apoptosis [95]. It was also discovered that after exposure to the anti-cancer drug 
paclitaxel, ovarian cancer cell lines (OV-MZ-6 and SKOV-3) survival rates were 
observed highly increased in cell spheroids grown in 3D hydrogels [64]. In the case 
of gene expression, oncogenic signals in organotypic neoplasia resembled gene 
expression profiles of orthotopic in vivo model and spontaneous clinical human 
cancers in 3D tissue, but not in 2D culture [94]. Then from gene to phenotype, 
Madin-Darby canine kidney (MDCK) cell culture in 3D collagen developed a 
differentiated polarized epithelium while collagen-coated 2D substrates induced a 
tumor-like phenotype with increased glycolysis and small up-regulation of proteins 
[6]. To the contrary, 3D culture of tumor cells usually results in the formation of 
hollow necrotic cores which recall observations in clinical tumor specimens, as 
suggested by Ghosh et al [99]. Today, the use of physiologically relevant in vitro 
3D model system seems to be a trend for its efficient biological resemblance in 
modern cancer research.  
 
Another approach to studying cancer is to use animal models to replicate 
the biological and physiological environment of cancer cells. Up to now, most 
commonly used animal models in drug screening and efficacy study is 
subcutaneous tumor xenograft, which allows for complex tumor-stromal cell 
interaction contributing to tumor formation and progression [72].  In this type of 
model, xenografts are established in immunodeficient mice on which tumor cells 
are injected beneath the skin [100]. The deficiency of a complete functional 
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immune system, however, may also affect tumor development [101]. Certain drug 
tests using xenografts have showed that many promising drugs were found 
irrelevant to suppressing of spontaneous tumor growth [102]–[104]. Other animal 
models include chemical carcinogenesis mouse model, radiation carcinogenesis 
mouse model, and murine genetic mouse model. However, in vivo studies by using 
mouse/animal models are also known for complexities, unpredictability and 
controversial ethical issues. Also, those animal models are not currently available 
to all cancer types [105]. For example, Khavari et al. reported a new platform on 
immune-deficient mice with regenerated human tissue, which could recapitulate 
many important features of an intact human skin in vivo [106]. But this general 
approach cannot be widely applied to other types of cancers because many visceral 
tissues do not have tissue regenerative characteristic like skin. In a recent study, 
Zheng et al. developed a novel orthotopic and metastatic mouse model for gastric 
cancer with human gastric microenvironment by injecting human gastric cancer 
cells [107]. Although this model could resemble tumor proliferation and metastases 
under the manipulated gastric microenvironment, the implanted human gastric 
tissues were difficult to survive perform normal function in mouse.  Here the animal 
model is still considered insufficient for immune research. It is certain that animal 
models have contributed to some key aspects of cancer biology, but their inherent 
xenograft immune characteristics often limit its applicability. It is also arguable that 
3D in vitro model could fully replace animal model in the future. Currently an 
animal model still serves as a useful validation benchmark. Still, the techniques in 
developing a 3D in vitro model can often be associated with an animal model [56], 
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e.g., 3D co-cultured cells introduced in mouse xenografts [108]. Therefore the 3D 
in vitro model is beneficial to cancer research as a fundamental structure, more than 
merely an evaluation tool. 
 
As previously mentioned, the recreation of tumor microenvironment 
including tumor-stromal interactions, cell-cell adhesion and cellular signaling is 
essential in cancer-related studies. Traditional two-dimensional cell culture and 
animal models have been proven to be valid in some area of explaining cancerous 
cell behaviors and interpreting hypotheses of possible mechanisms. However, a 
well-defined in vitro cancer model, which mimics tumor structures found in vivo 
and allows cell-cell and cell-matrix interactions, has gained strong interests for a 
wide variety of diagnostic and therapeutic applications. This section attempts to 
provide a representative overview of applying in vitro biological model systems for 
cancer related studies. Recent technologies to construct and develop in vitro cancer 
models are summarized in aspects of modeling design, fabrication technique and 
potential application to biology, pathogenesis study and drug testing. With the help 
of advanced engineering techniques, the development of a novel cancer cell-on-a 
chip device as an in vitro cancer model will provide a better opportunity to 
understand crucial cancer mechanisms and to develop new clinical therapies. 
 
1.5 Research Objective and Activities 
The objective of this thesis is to develop scientific and engineering 
knowledge in surface functionalization of substrate surface through global and local 
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plasma treatment to understand how cellular functions respond to multiple cues 
from their microenvironment. This thesis presents; the utilization of plasma 
chemistry to enhance surface functionalization, development of an engineering 
model for local plasma treatment, integration of biofabrication processes to 
assemble cell-on-a-chip device. 
 
The specific activities presented in thesis are: 
1) Integration of a dual-function freeform microplasma surface 
patterning and bioprinting process to produce maskless micro-size patterns and 
print biomolecules or living cells; 
2) Study of the enhancement of cell attachment, proliferation, and 
differentiation by modification of the surface properties with microplasma surface 
treatment; 
3) Development of an engineering model to quantify the degree of 
surface functionalization generated by microplasma patterning process as a 
function of key process parameters; 
4) Fabrication and validation of a cell-on-a-chip device for cancer 
research with an integrated multifunctional biofabrication system 
 
1.6 Thesis Outline 
This thesis is outlined as follows: 
Chapter 2 discussed the effect of oxygen-based global plasma surface 
modification of polycaprolactone (PCL) samples on cellular functions. This chapter 
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illustrated the manufacturing and oxygen-based plasma modification processes of 
PCL samples. The methods in surface and biological characterization of plasma 
modified PCL sample were described in details. Changes in surface 
physicochemical properties by oxygen-based plasma modification improved cell-
surface interaction. 
 
Chapter 3 presented an atmospheric-pressure microplasma jet based on 
dielectric barrier discharge (DBD) was installed on an automated arm of a patented 
cell printer which allows movement in the x-y-z directions at various trajectory 
presets. PCL samples were functionalized with helium-oxygen plasma generated 
by this system and characterized via water contact angle (WCA), X-ray 
photoelectron spectroscopy (XPS), and scanning electron microscopy (SEM). The 
surface and biological characterization results indicate that microplasma treatment 
improved surface hydrophilicity, as well as cell viability and proliferation. 
 
Chapter 4 presented a two-dimensional (2D) plasma simulation-statistical 
model of the atmospheric-pressure microplasma jet described in Chapter 3. The 
effect of mass species transport to polymer surface was investigated by coupling an 
incompressible fluid dynamics model to a plasma kinetics model. The modeling 
results involve tracking the different physical processes such as discharge 
breakdown, radical chemistry and surface kinetics occurring at and after ignition 
of gas discharge. 
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Chapter 5 investigated the integration of maskless fabrication techniques to 
develop cell-on-a-chip devices. The integrated multifunctional fabrication system 
eliminates the limitations of conventional photo-lithography and provides its end-
users with the capabilities to develop advantageous cell-on-a-chip, organ-on-a-chip, 
and body-on-a-chip platforms. This chapter also illustrated the capabilities, beneﬁts, 
and challenges of the integrated multifunctional biofabrication system to develop 
biological microﬂuidics. Several biological investigations were presented to 
demonstrate the system’s capabilities to produce an advanced cancer cell-on-a-chip 
device. 
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CHAPTER 2: GLOBAL PLASMA TREATMENT FOR BIOPOLYMER 
SURFACE MODIFICATION  
2.1 Categories of Plasmas 
In 1927, Nobel Laureate Irving Langmuir named ionized gas, plasma. Since 
the later 1920s, numerous efforts have been made to generate, sustain, and utilize 
this special type of matter (referred to as the fourth state of matter). Plasma have 
been used in versatile applications, such as lasers, light sources, etching of surfaces, 
and deposition of chemicals [109]–[113]. Plasma raises countless new challenges 
in the principles of physics, chemistry, engineering, biology, and medicine. The 
plasma state of any matter is obtained when gas is excited into energetic states by 
radio-frequency (RF), microwave (MW) or electrons from a high-temperature 
filament discharge [16]. Plasma can be categorized into two main groups; high 
temperature and low temperature (or gas discharge). High temperature plasma 
specifies that all the species including electrons, ions, and neutral species are in a 
thermal equilibrium state. Low temperature plasma includes thermal plasma known 
as quasi-equilibrium plasma, and non-thermal plasma, known as non-equilibrium 
plasma or cold plasma [112]. Figure 2 shows a typical cold plasma dielectric barrier 
discharge (DBD). DBD plasma can be generated in various working dielectric 
mediums through ionization by high frequency and high voltage electric discharges 
[114]. The existence of dielectric barrier reduced temperature and scales of plasma 
filaments. DBD plasma is widely used in biological applications for surface 
functionalization. 
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2.2 Polycaprolactone Sample Preparation 
Polycaprolactone (PCL) is a biodegradable thermoplastic polymer widely 
used in the field of tissue engineering. It has a low melting point of 60 °C and is 
often used as a feedstock for prototyping systems. PCL was approved and regulated 
by the U.S. Food and Drug Administration (FDA). It is frequently investigated as 
a scaffold material for use in bone regeneration due to its biocompatibility. 
 
A glass mold was manufactured to fabricate the PCL samples for 
experimental use. The height of the empty mold space is 0.75 mm. The glass mold 
 
Figure 2. Images of DBD plasma ignition under different process parameters (A: 4kV; B: 6kV). 
A B
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base was first placed on a hotplate and preheated up to 100 °C. A batch of PCL 
(Sigma-Aldrich, St. Louis, MO) beads was then distributed at designated spots on 
the glass mold base. After the PCL beads were fully melted, a new batch of beads 
was added. The final step was repeated until a total of four batches of beads were 
melted. A glass cover was placed over the glass mold base, both ends clipped 
subsequently. The set was removed from the hotplate and passively cooled to room 
temperature. The PCL samples were collected after the glass cover was removed. 
Each fabricated PCL sample had a smooth surface with a diameter of 12.5 mm and 
a thickness of 0.75 mm, allowing it to fit 24-well cell culture plates for the use of 
future biology studies (Figure 3). At the preparation stage, two cuts were made at 
the edges on each PCL sample to indicate its centerline. The PCL samples were 
rinsed in 95% alcohol for 30 minutes. They were collected and later placed under 
microplasma nozzle for plasma treatment (Figure 4). 
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Figure 3. Preparation of PCL samples in a 24-well cell culture plates for plasma treatment. 
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2.3 Plasma Surface Modification and Characterization 
To investigate the effects of global plasma modification, sterile 
polycaprolactone (PCL) samples were modified with a plasma reactor (PDC 32G, 
Harrick Plasma, New York). The plasma reactor consists of radio-frenquency (RF 
13.56 MHz) powered coils around the shell of plasma chamber with gas feeding 
inlet and vacuum pumping outlet. The PCL samples were placed in the plasma 
chamber and oxygen (O2) was purged to the chamber at flow rate of 1 slpm by an 
integrated gas feeding system. During the global plasma treatment, the plasma 
chamber was maintained at a low pressure (~200 mTorr) through vacuum pump 
 
Figure 4. Fabricated PCL samples stored in a petri dish. 
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with a pumping speed of 6 m3/hr. Generally a 100 W of RF power was applied to 
create high-frequency magnetic field to breakdown the gas and sustain the plasma. 
The plasma generated modified the PCL sample surface globally therefore a 
uniformly can be expected. After the plasma modification, the samples were 
transferred to a laminar air flow biological safety cabinet for further 
characterizations. 
 
The corresponding contact angles were measured to evaluate the effect of 
the applied global plasma surface modification techniques. This study quantifies 
PCL’s degree of hydrophilicty and surface wettability. The water contact angle 
(WCA) of probe liquids on modified and unmodified PCL sample surfaces were 
measured by a sessile drop technique. In this technique, once the probe liquid is 
dropped to the surface, the image of the droplet is taken using a video-camera 
mounted on a microscope. Ultrapure water was provided from Agilent 
Technologies (Germany). Before starting contact angle measurement, a drop of 
probe liquid (2µL) was placed on modified and unmodified PCL sample surfaces 
at room temperature. Once the liquid had settled (become sessile), droplet images 
were taken then transferred to ImageJ software (NIH, Bethesda, Maryland). Figure 
5 shows a plugin in ImageJ for measuring the actual contact angles [115]. 
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The effect of plasma modification on surface hydrophilicity was measured 
by the contact angle on unmodified and plasma modified PCL surfaces, and the 
 
Figure 5. Drop shape analyses using ImageJ with contact angle measurement plugin (A: drop on 
native PCL sample; B: drop on plasma-treated PCL sample). 
 
A
B
23 
 
 
results are shown in Figure 6. After fabrication, the contact angles of the native 
PCL samples were around 80°. The results of the contact angle measurement 
indicated showed that the contact angles decreased significantly after the plasma 
modification, which means that the surface hydrophilicity increases as a result of 
the plasma surface treatment.  
 
 
 
2.4 Biological Investigations 
7F2 cells are acquired from American Type Culture Collection (ATCC, 
Manassas, VA). The cells were cultured in 90% alpha minimum essential medium 
with 2 mM l-glutamine and 1 mM sodium pyruvate (Sigma-Aldrich, St. Louis, 
MO), and with 10% fetal bovine serum (Gibco, Grand Island, NY). Cells were 
maintained in incubator equilibrated with 5% carbon dioxide (CO2) at 37 °C. At 
confluency, cells were trypsinized, counted and re-suspended to a cell density of 
 
Figure 6. Effect of changing plasma treatment time on WCA for PCL (sample size: n=3). 
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1×106 cells/mL. Culture medium was changed every 2 to 3 days. The cell-polymer 
constructs were maintained in an incubator (37°C and 5% CO2) for further analysis. 
 
A MarkerGene™ Live:Dead/Cytoxicity assay kit was used to analyze the 
cell viability and cytotoxicity. A Live:Dead solution was created using propidium 
iodide with carboxyfluorescein diacetate according to the manufacturer’s protocols. 
The damaged cells were marked fluorescently red and the intact cells were marked 
green by carboxyfluorescein dye. Red fluorescence could be observed with 
excitation and emission at 493 nm and 630 nm, respectively. Green fluorescence 
could be observed with excitation and emission at 475 nm and 517 nm, respectively. 
Figure 7 shows a comparison of Live:Dead fluorescent images of 7F2 cells attached 
to treated and native PCL samples. An alamarBlue® Kit (AbD Serotec, Raleigh, 
NC) was used to determine cell proliferation rates. The excitation and emission 
wavelengths for alamarBlue® assay were 535 and 590 nm, respectively. 
Quantitative data for cell viability and proliferation were collected using the 
microplate reader (GENios, Tecan Systems, San Jose, CA). 
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Figure 7. Live:Dead fluorescent images of 7F2 cells attached to (A) plasma-treated and (B) control 
PCL samples. 
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The studies of cellular response aim to identify the effects of a microplasma-
functionalized area on cell activities including attachment, proliferation, and 
differentiation. After being plasma treated for 1 minute, the functionalized area of 
the biopolymer was seeded with cells. AlamarBlue® assay, which incorporates a 
fluorometric indicator directly based on proportional relationship between 
fluorescence intensity and cell viability, was used to quantify cell proliferation. 
Live:Dead assay was used to measure the metabolic activity of cells. The 7F2 cells 
were later seeded on both treated and native PCL samples following standard cell 
culture protocol described previously. Figure 8 shows that the microplasma 
treatment improved both cell viability and proliferation at 6 hour, 12 hour, 18 hour, 
and 24 hour time points (n = 3). The peak of fluorescence intensity for both plasma 
treated and control group appears at 24 hour time point. 
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Figure 8. 7F2 cell viability and proliferation on PCL samples (A: cell viability results from 
Live:Dead assays; B: cell proliferation results from alamarBlue® assays; sample size: n=3). 
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CHAPTER 3: DEVELOPMENT OF A LOCALIZED FREEFORM 
MASKLESS MICROPLASMA PATTERNING SYSTEM 
This work first appeared in [116] and was done in collaboration with Qudus Hamid, 
Jessica Snyder, Halim Ayan, and Wei Sun. 
3.1 Surface Treatment Techniques 
The ability to manipulate structural and biochemical cues plays an 
important role in regulating cell behavior during the biofabrication process for a 
wide range of diagnostic and therapeutic applications [117], [118]. In a living tissue 
environment, cells and proteins are surrounded by topographic and biochemical 
cues, which assist with cell attachment and provide guidance for cell-cell and cell-
substrate interactions [119], [120]. In nature, these cues are inherent to the native 
biological system [121], [122]. However, most biopolymers that are currently 
utilized in tissue engineering often lack adequate surface structural or biochemical 
cues. To enhance the surface functionality of biopolymers, a variety of techniques 
have been used. For example, conventional photolithography [123]–[129], soft 
lithography [130], [131], microcontact printing [132], [133], self-assembled 
monolayers (SAMs) [134]–[136], direct writing [137], and laser ablation [138]. 
These surface treatment techniques can provide additional structural, chemical, and 
biological cues that regulate cell morphologies as well as subsequent cellular 
function [139]–[141]. In most of the aforementioned techniques, surface 
functionalization is achieved by applying cell-adhesive and cell-repellant 
biomolecules to the surface through patterned masks or master stamps. Though 
effective, the preparation of patterned masks and/or master stamps is often a costly 
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process in terms of both time and resources (e.g., the need to use special clean room 
instrumentation) [142]–[145]. The harsh chemicals and solvents used in these 
processes can damage the patterned bio-organic layers [145], [146]. Additionally, 
the use of patterned masks or master stamps is very difficult to achieve a controlled 
surface gradient, especially on surfaces with complex geometries [147], [148]. 
 
Due to these limitations, maskless plasma-based surface treatment has 
recently gained considerable interest [149]–[154]. Assisted plasma polymerization 
and coating could benefit photolithographic processes in fabricating biosensors 
[155]. Plasma-induced biopolymer surface functionalization has been reported to 
improve the biocompatibility of biomaterials for nerve repair by enhancing cellular 
responses [156]. Microplasma discharges technologies (miniaturization of the 
plasma down to characteristic micro feature size) have a broad range of applications 
in display panels [157], materials processing [158], [159], analytical instruments 
[160], decontamination of living human tissue [161], [162], and “plasma needles” 
for surgery [163], [164]. Though versatile and efficient, most enabling plasma 
technologies use “hot” plasma dischargers and operate under low pressure (below 
atmospheric pressure), which makes them a difficult tool for treatment of heat-
sensitive biopolymers and biological substrates. Additionally, conventional plasma 
needle discharges are on the order of millimeters in size [163]–[165] and are 
incapable of producing the micro-scale surface patterning suitable to cell and 
biomolecule patterns. This chapter presents a localized atmospheric-pressure and 
non-thermal microplasma surface functionalization technique to produce maskless 
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and chemical-free (non-hazardous) surface patterning. The freeform microplasma 
surface patterning process is able to produce the desired structural and chemical 
cues simultaneously to enhance the surface properties of biopolymers for tissue 
engineering applications.  
 
3.2 Freeform Maskless Microplasma System 
DBDs are non-equilibrium plasma that operates under atmospheric pressure 
[166]. Due to a non-equilibrium nature, DBD plasmas can generate high energy 
electrons at cool background gas temperatures (heavy particles). This unique 
character (selective high electron temperature, and low background temperature) 
enables a rich plasma chemistry in many plasma chemical processes [167]. 
 
In this chapter, an employed microplasma was generated by a variable 
frequency power supply with the DBD technique. The microplasma system is 
integrated with a freeform fabrication-based biomolecule printing system to 
perform the dual functions of freeform generation of microplasma surface patterns 
and printing biomolecules and cells. The microplasma first functionalizes the 
biopolymer surface based on the designed pattern and then bioprinting system 
prints cells or biomolecules on the generated pattern surfaces. 
 
The plasma electrode system is composed of a high voltage metal electrode 
(copper, 1 mm in diameter) coaxially inserted in a dielectric tube (borosilicate glass, 
6.5 mm in outer diameter, 0.2 mm in thickness), with a ground metal electrode 
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(copper, 0.4 mm in thickness) wrapped around the tube from the outside. The 
process gas (or gas mixture) is purged through the annular gap between the coaxial 
electrode and the dielectric tube. When the high voltage electrode is powered, 
plasma ignited between the electrodes and a micron-scale plasma appears at the tip 
of the nozzle. Once the microplasma contacts the surface of the biopolymer, it 
changes the topography and chemistry of the plasma-exposed area. The voltage and 
current data were acquired through a 100MHz digital oscilloscope (Tektronix 
TDS2014C, Tektronix Inc., Beaverton, OR) with a 1000× high voltage probe 
(Tektronix P6015A, Tektronix Inc., Beaverton, OR) and a 1 V/A current monitor 
(Pearson 4100, Pearson Electronics Inc., Palo Alto, CA). Figure 9 shows a 
schematic view of the microplasma system and its components. Depending on the 
microplasma operation parameters such as plasma power, gas flowrate, gas 
composition, and nozzle tip diameter, a certain level of control on the chemical 
composition and topological features of the biopolymer surface can be obtained 
(Figure 10).  
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Figure 9 Structure of microplasma jet. (A: schematic; B: photography). 
A
B
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The micro-scale plasma nozzle tips were manufactured using a P-2000 
Micropipette Puller following a preset of parameters for repeatability. Micro-nozzle 
tips with inner diameters at the tip ranging from 50 µm to 500 µm were fabricated 
and latter connected to the borosilicate glass Pasteur pipettes; the joints were sealed 
by light cure adhesive (Loctite 35241 352, Henkel Corp., Rocky Hill, CT). Two 
microscopic images are presented in Figure 11 to demonstrate various sized plasma 
 
Figure 10. The flow chart of the microplasma system. 
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nozzle tips. It should be noted that the cracks around the nozzle tip are common 
and is due to the manufacturing process of pulling. 
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Figure 11. Microscopic images of plasma nozzle tips with different nozzle diameters (A: 50 
µm; B: 250 µm). 
A
B
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In order to create a pattern and control the shape of the pattern over the 
biopolymer surface, the microplasma system is operated by a data processing and 
motion control system. The data processing system converts the CAD model or 
designed pattern into a layered process tool path. The 3D motion system consists 
of x-, y-, and z-axes, which were actuated by AC servo motors driven by servo 
drivers (Parker Hannifin Corp, Cleveland, OH). Through the data processing and 
3D motion system, users are able to define the path for the microplasma nozzle 
such that it follows the path of the surface patterning without using any mask or 
master stamps.  
 
To study the effect of gas composition on surface change, oxygen (O2) is 
required to produce active oxygen species for the functionalization of the 
biopolymer surface. However, oxygen is a highly electronegative gas and causes 
excessive attachment and eventually quenching of the discharge if it is not 
accompanied by another gas that can sustain stable non-thermal plasma, such as 
helium (He). Figure 12 shows the effect of changing gas composition on the 
appearance of microplasma discharge. Other tunable parameters includes; voltage, 
frequency, traveling speed, nozzle size, and displacement from nozzle tip to sample 
surface. A line/curve pattern of plasma treatment on each sample can be performed 
via the automation platform following a set of predefined working parameters 
(Table 1). The microplasma jet operates at room temperature (~300K). At higher 
power settings arcing would occur (temperature would increase). 
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Two separate voltage-current waveforms of the microplasma discharge 
(operating in the helium/oxygen gas mixture) demonstrating the plasma system’s 
capabilities are shown in Figure 13. The voltage is 6 kV peak-peak with frequency 
 
Figure 12. Photographs of microplasma jet (A: no discharge; B: discharge from 100% helium; 
C: discharge from 99% helium.and 1% oxygen; exposure time: 12.5 ms). 
A B C
Table 1. Typical working parameters for microplasma surface functionalization. 
Working Parameters Value Unit 
Voltage 3 kV 
Frequency 20 kHz 
Helium flowrate 0.5 slpm 
Oxygen flowrate 5 sccm 
Traveling speed 0.5 mm/s 
Nozzle size 150 µm 
Distance from nozzle tip to sample surface 1 mm 
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set to be 25 kHz. The numerous current spikes in every half cycle of the voltage 
waveform, represent microdischarges occurring in the atmospheric microplasma jet. 
 
 
 
3.3 Surface Modification of Polycaprolactone 
PCL samples were fabricated following the same procedures detailed in 
section 2.2. To analyze the modifications on a microplasma patterned surface, water 
contact angle (WCA) and X-ray photoelectron spectroscopy (XPS) served as 
quantitative methods; the study of surface topography using scanning electron 
microscopy (SEM) and atomic force microscopy (AFM) as qualitative methods 
provides more intuitive results. WCA images were captured via a Basler A601f 
camera (Basler Vision Technologies, Exton, PA) and a Fiber-Lite MI-150 light 
source (Dolan-Jenner Industries, Boxborough, MA). XPS data were acquired using 
 
Figure 13. Voltage-Current waveforms of microplasma discharges in helium-oxygen gas 
mixture (1% O2, 99% He) with voltage of 6 kV peak to peak. 
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VersaProbe 5000 (Physical Electronics, Chanhassen, MN) with a monochromatic 
Al Kα X-ray source. SEM images were obtained using an FEI/Philips XL-30 Field 
Emission Environmental Scanning Electron Microscope (FEI, Hillsboro, OR). 
AFM images and data were obtained using Asylum MFP-3D Classic (Asylum 
Research, Santa Barbara, CA). 
 
3.3.1 Water Contact Angle Measurements 
Local plasma treatment of PCL samples were completed following the 
parameters from Table 1 unless stated otherwise. The plasma-treated and native 
samples of PCL were examined by the water contact angle technique. 2 µL of 
deionized water was dispensed from pipette tips (describe the technique of 
“placement”) to the center of each sample and its profile was examined by a 
goniometer. WCA measurements were characterized via a drop shape analysis 
plug-in on ImageJ software (NIH), using the fitting of the Young-Laplace equation 
to the image data (Figure 14).  
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The WCA values directly correlate with the surface wettability and 
 
Figure 14. Comparison of water contact angles on PCL samples (A: native, θ = 82.92°; B: 
plasma-treated, θ = 61.18°). 
θ
θ
A
B
41 
 
 
hydrophilicity in a reverse ratio. After fabrication, the contact angles of the native 
PCL samples are around 80°. Figure 15 represents the effect of changing the 
distance between the nozzle tip and the sample surface (sample size: n = 3). As the 
traveling speed and the distance increased, the effect of the plasma treatment 
weakened as higher WCA values were observed. Figure 16 presents the effect of 
power frequency on WCA at a distance of 1 mm from nozzle tip to sample surface 
for PCL. This figure indicates that as the traveling speed increased, the effect of 
plasma treatment weakened as higher WCA values were observed, which follows 
the same trend in Figure 15 (n = 3). However, the effect of changing power 
frequency is not linear with the increase in WCA value. The lowest values are 
observed at 20 kHz, indicating that this frequency is an optimal setting for current 
experiments to pursue better wettability and hydrophilicity (crucial for cell 
attachment). Compared to literature results [168], the WCAs in this study are higher 
due to a few factors that include different system configuration, lower power 
settings, shorter treatment time, etc. 
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Figure 15. Effect of changing distances from nozzle tip to sample surface on WCA for PCL 
(power frequency: 30 kHz; sample size: n=3). 
 
 
Figure 16. Effect of changing power frequencies on WCA for PCL (distances from nozzle tip 
to sample surface: 1 mm; sample size: n=3). 
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3.3.2 Surface Morphology 
To visualize the surface change on the PCL samples, surface morphology 
images were taken via a scanning electron microscope (Zeiss Supra 50VP, Carl 
Zeiss Microscopy, Thornwood, NY). A single line path was programmed to be 
performed across the center of the round sample of PCL. The PCL samples were 
functionalized following the parameters from Table I and then transferred for SEM 
imaging.  
 
In the SEM images shown in Figure 17, the line pattern produced by the 
microplasma is visible. The line pattern can be easily differentiated from an 
untreated ‘background’, as a result of change in surface morphology. The nozzle 
size was 150 μm, and the visible line pattern’s width was approximately 55 μm. 
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Figure 17. SEM images of the microplasma pattern: (A: general view; B: closed-up view). 
500 µm
200 µm
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The topology change was further validated by AFM images. The results of the root-
mean-square-roughness (RMSR) for unmodified and plasma modified PCL are 
given in Table 2, with the ± representing the standard deviation of roughness for 
each modification measurement (sample size: n=3). After a quick microplasma 
treatment, surface root mean square roughness increased approximately 20%.  
 
Wenzel’s theory relates the water contact angle for a surface to that of a 
smooth surface through a roughness factor r (r>1): 
𝑟 =
𝑐𝑜𝑠𝜃𝑟𝑜𝑢𝑔ℎ
𝑐𝑜𝑠𝜃𝑠𝑚𝑜𝑜𝑡ℎ
 
This equation indicates that if the surface has a contact angle of less than 90°, the 
angle will be decreased by an increase in surface roughness. PCL has a native 
contact angle less than 90°, therefore the more aggressive the plasma treatment, the 
rougher the surface, and the smaller value of contact angle [169]. 
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Figure 18. AFM images of (A) native and (B) modified PCL surfaces. 
A
B
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3.3.3 X-Ray Photoelectron Spectroscopy (XPS) Analysis 
X-ray photoelectron spectroscopy (XPS) from Centralized Research 
Facilities of Drexel University were used to analyze the surface chemistry change, 
especially surface chemical composition and functional group introduction. Two 
survey XPS spectra were presented to show the major chemical elements on the 
surfaces of both unmodified and modified (plasma-treated) samples (Figure 19). 
The surface atomic concentrations of atomic carbon, oxygen, and silicon are 
presented in Table 3.  
Table 2. Surface root mean square roughness (RMSR) for unmodified and modified PCL. 
Substrate Type Surface Root Mean Square Roughness 
Native 43±5 
Modified 52±8 
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Figure 19. Survey XPS spectra of PCL before and after plasma treatment. 
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Certain concentrations of silicon were found in the PCL sample; it may be 
due to the fabrication process with glass mold and/or the preparation step for XPS 
analysis. After microplasma treatment, there was a significant decline in silicon 
concentrations, which could be a result of increased carbon and oxygen functional 
groups on the surface, introduced by plasma treatment. 
 
To further investigate the functional group change on the PCL surface, high-
resolution XPS spectra of carbon were acquired. Deconvolution of C1s peak was 
conducted by a non-linear least square curve-fitting program MultiPak (Physical 
Electronics, Chanhassen, MN) along with comparison to literature data [170]. The 
fractions of carbon-based functional groups are tabulated in Table 4.  
 
Table 3. Surface atomic concentrations of native and modified PCL surfaces. 
Substrate Type 
Atomic Concentration (%) 
C O Si 
Native 63.1 30.4 6.5 
Modified 78.3 27.8 1.9 
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Figure 20 shows high-resolution XPS spectrum of carbon on unmodified 
and modified (plasma-treated) PCL surfaces. Before microplasma modification, 
graphitic (C1), hydroxyl (C2), and carboxyl (C3) groups are found in the XPS 
spectrum, with a peak at 283.9 eV, 285.3 eV, and 288.0 eV, respectively. A new 
functional group, a carbonyl group with a peak at 286.1 eV, was observed in the 
XPS spectrum of the plasma functionalized sample surface. This suggests that 
plasma-induced reactions occurred on the surface of PCL, which changed the 
surface morphology (as observed before) and the surface chemistry.  
 
Table 4. Fractions of functional groups of native and modified PCL surfaces. 
Substrate 
Type 
Fraction of functional groups (%) 
Graphitic 
C-C, C-H 
283.9 eV; 
(C1) 
Hydroxyl 
C-OH 
285.3 eV; (C2) 
Carboxyl 
-O-C=O-COOH 
288.0 eV; (C3) 
Carbonyl 
C=O 
286.1 eV; (C4) 
Native 74.85 17.01 8.14 NA 
Modified 77.77 11.39 8.15 2.68 
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Figure 20. High-resolution C1s XPS spectra of PCL before and after plasma treatment. 
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3.4 Biological Investigations 
7F2 cells are acquired from American Type Culture Collection (ATCC, 
Manassas, VA). The cells were cultured in 90% alpha minimum essential medium 
with 2 mM l-glutamine and 1 mM sodium pyruvate (Sigma-Aldrich, St. Louis, 
MO), and with 10% fetal bovine serum (Gibco, Grand Island, NY). Cells were 
maintained in incubator equilibrated with 5% carbon dioxide (CO2) at 37 °C. At 
confluency, cells were trypsinized, counted and re-suspended to a cell density of 
1×106 cells/mL. Culture medium was changed every 2 to 3 days. 
 
A MarkerGene™ Live:Dead/Cytoxicity assay kit was used to analyze cell 
viability and cytotoxicity. A Live:Dead solution was created using propidium 
iodide with carboxyfluorescein diacetate according to the manufacturer’s protocols. 
The damaged cells were marked fluorescently red and the intact cells were marked 
green by carboxyfluorescein dye. Red fluorescence could be observed with 
excitation and emission at 493 nm and 630 nm, respectively. Green fluorescence 
could be observed with excitation and emission at 475 nm and 517 nm, respectively. 
An alamarBlue® Kit (AbD Serotec, Raleigh, NC) was used to determine cell 
proliferation rates. The excitation and emission wavelengths for alamarBlue® 
assay were 535 and 590 nm, respectively. Quantitative data for cell viability and 
proliferation were collected using the microplate reader (GENios, Tecan Systems, 
San Jose, CA). 
 
The studies of cellular response aim to identify the effects of a microplasma-
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functionalized area on cell activities including attachment, proliferation, and 
differentiation. After being microplasma patterned, the functionalized area of the 
biopolymer was seeded with cells. AlamarBlue® assay, which incorporates a 
fluorometric indicator directly based on proportional relationship between 
fluorescence intensity and cell viability, was used to quantify cell proliferation. 
Live:Dead assay was used to measure the metabolic activity of cells. The 
morphology of cells attached to a PCL sample surface was examined by SEM. 
 
In previous studies, [54] the results indicated that 1% O2 (He at 0.5 slpm, 
O2 at 5 sccm) was the optimal gas composition of plasma treatment for cell studies. 
A line pattern microplasma treatment was performed on each PCL sample using 
the working parameters in Table 1. The 7F2 cells were later seeded on both treated 
and native PCL samples following standard cell culture protocol described 
previously. Figure 21 shows that the microplasma treatment improved both cell 
viability and proliferation at 6 hour, 12 hour, 18 hour, and 24 hour time points (n = 
3). The peak of fluorescence intensity for both plasma treated and control group 
appears at 24 hour time point, with the former being 1.5 times as large as the latter. 
Fluorescent images were taken 24 hours to observe cellular activity. Figure 22 
shows a high density of cells on functionalized PCL sample surface in comparison 
to a low cell density on native PCL sample surface (n = 3). This further validates 
that cells selectively adhered to the plasma patterned area. Microplasma treatment 
on the PCL surfaces resulted in oxygen-related functional groups such as C-O, 
C=O, and O=C-O, which could improve the attachment of cells. Compared to the 
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microplasma pattern in Figure 22, the cells were observed to occupy a wider area, 
which could be a result of cell spreading and migration over time. 
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Figure 21. 7F2 cell viability and proliferation on PCL samples (A: cell viability results from 
Live:Dead assays; B: cell proliferation results from alamarBlue® assays; sample size: n=3). 
A
B
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Figure 22. Fluorescent images of 7F2 cells on PCL samples after 24 hours (top: cells on 
microplasma patterned surface; bottom: cells on native surface; magnification: 10X). 
100 μm
100 μm
A
B
57 
 
 
SEM images were taken after 24 hours of incubation to better visualize the 
morphology of cells. Figure 23 presents a close-up SEM image of 7F2 cells well 
spread and attached to the functionalized surface on PCL sample. An elongated, 
rather than round cell, morphology was also observed in this image. These studies 
indicate that the localized microplasma treatment improved surface morphology 
and chemistry, caused an increase in hydrophilicity, and thus improved cell 
viability and proliferation. It was reported that oxygen functional groups were able 
to minimize the free energy of the interface between polymer surface and the 
surrounding medium [171]. Also, oxygen-based plasma discharge generates 
oxygen radicals which polarize the surface and surface becomes negatively 
charged. The negative charge attracts proteins (supplemented with serum) from the 
media as adhesion factors [172]. This localized microplasma treatment has the 
potential to pioneer bioactive PCL scaffolds with selective surface 
functionalization for applications in bone tissue engineering, etc. 
 
58 
 
 
  
 
Figure 23. Scanning electron microscopy (SEM) images of cells on a microplasma patterned 
area of PCL sample after 24 hours (magnification: 1000X). 
20 μm
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CHAPTER 4: MODELING OF A DIELECTRIC BARRIER DISCHARGE 
(DBD) MICROPLASMA JET 
4.1 Plasma Modeling in General 
Through optimized biomaterial selection, fabrication methods, physical, chemical, 
and biological surface modification techniques, researchers are able to control 
cellular functions of their tissue/cell platform’s environment [173]. However, 
identifying the appropriate surface modification parameters and cues through 
experimental studies might be time consuming and costly. Researchers have been 
developing numerous models to predict the degree of surface functionalization 
from plasma modification and changes in surface physical and chemical properties 
[174]. Some early attempts were made by Graves and Humbird to simulate plasma 
etching of silicon using a molecular dynamics model [1]. In a highly cited journal 
article, Sakiyama and Graves presented a RF (13.56 MHz) two-dimensional 
axisymmetric numerical model of a plasma needle in helium to observe the 
expansion of charged species [2]. Bhoj and Kushner created a two-dimensional 
plasma hydrodynamics-surface kinetics model of Helium/Oxygen/Water plasma to 
investigate species accumulation on polypropylene [3]. In a review article, 
Schwaederle et al. summarized modeling plasma and plasma-surface interactions 
with several techniques, including fluid modeling, Monte Carlo (MC) simulations, 
Particle-in-Cell-Monte Carlo Collisions (PIC-MCC) simulations, hybrid Monte 
Carlo-Fluid Modeling Network, and molecular dynamics simulations [4]. Most 
models mentioned in these studies are case-specific and cannot be applied to other 
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systems. Therefore, a specific model need to be developed to predict the degree of 
surface functionalization, while reducing the input of extensive experiment data. 
  
4.2 Plasma Kinetics Model Overview 
In a typical dielectric barrier discharge (DBD) setting, there is a small gap filled 
with a feeding gas in between a high voltage electrode and a grounded dielectric 
barrier. The gap is typically several millimeters. In this chapter a 2D axisymmetric 
cylindrical model is development to capture the characteristics of DBD with He/O2 
mixture. In the cylindrical model, a sinusoidal voltage is applied on the inner 
electrode while the outer electrode is grounded. The geometry for a typical 
dielectric barrier discharge is shown in Figure 1. 
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As the voltage applied to the center electrode increases, a stronger electric field 
forms in the gap between the electrodes. Any free electrons in the gap will be 
accelerated and if the electric field is strong enough they may acquire enough 
energy to cause ionization. This can lead to a cascade effect where the number of 
electrons in the gap increases exponentially on a nanosecond timescale. Electrons 
created via electron impact ionization rush towards dielectric barrier, in the 
opposite direction to the electric field. An equal number of ions are also generated 
 
Figure 24. Graphic illustration of the cylindrical dielectric barrier discharge model; maximum 
height = 60 mm. 
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during electron impact ionization (electrons and ions must be created in equal pairs 
to preserve the overall charge balance). As a result, surface charge with opposite 
sign accumulates on the dielectric barrier. This causes the electric field to become 
shielded from the gas filled gap. In fact, the electric field across the gap cannot 
exceed the breakdown electric field, which is highly dependent on the gas. The 
breakdown electric field is also a function of the surface properties of the dielectric 
material. Surface charge accumulation temporarily terminates the discharge until 
the field reverses direction and the process repeats in the opposing direction. 
 
Modeling dielectric barrier discharges in more than one dimension is possible, but 
the results can be difficult to interpret due to the amount of competing physics in 
the problem. In this chapter the problem is reduced to a 2D axisymmetric 
cylindrical model. It allows us to quickly gain some insight into the characteristics 
of the discharge without excessive computation time. 
 
4.2.1 Domain Equations  
Most of the following domain and boundary equations come from the commercial 
finite element software COMSOL Multiphysics (Burlington, MA). 
 
Electron density 𝑛𝑒 and mean electron energy 𝑛𝜀 are solved from a pair of drift-
diffusion equations (convection of electrons due to fluid motion is neglected  
):  
𝜕(𝑛𝑒)
𝜕𝑡
+ ∇ ⋅ [−𝑛𝑒(𝜇𝑒 ⋅ 𝐸) − 𝐷𝑒 ⋅ ∇𝑛𝑒] = 𝑅𝑒    (𝐸𝑞.  1) 
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𝜕(𝑛𝜀)
𝜕𝑡
+ ∇ ⋅ [−𝑛𝜀(𝜇𝜀 ⋅ 𝐸) − 𝐷𝜀 ⋅ ∇𝑛𝜀] = 𝑅𝜀    (𝐸𝑞.  2) 
where 𝑛𝑒 is electron density, 𝑛𝜀 is mean electron energy, 𝜇𝑒  is electron mobility, 
𝜇𝜀  is energy mobility, 𝐷𝑒  is electron diffusivity, 𝐷𝜖  is energy diffusivity, 𝑅𝑒  is 
electron source, and 𝑅ε is energy loss due to inelastic collisions. 
 
The electron diffusivity 𝐷𝑒, energy mobility 𝜇𝜀, and energy diffusivity 𝐷𝜖 can be 
calculated from the electron mobility 𝜇𝑒  and electron temperature 𝑇𝑒 using the 
following equations: 
𝐷𝑒 = 𝜇𝑒𝑇𝑒, 𝜇𝜀 = (
5
3
) 𝜇𝑒, 𝐷𝜖 = 𝜇𝜀𝑇𝑒   (𝐸𝑞.  3) 
where 𝐷𝑒 is electron diffusivity, 𝜇𝜀 is energy mobility, 𝐷𝜖 is energy diffusivity, 𝜇𝑒  
is electron mobility, and 𝑇𝑒 is electron temperature 
 
Electron source 𝑅𝑒 is defined as: 
𝑅𝑒 = ∑ 𝑥𝑗𝑘𝑗𝑁𝑛𝑛𝑒
𝑀
𝑗=1
 (𝐸𝑞.  4) 
where 𝑥𝑗 is mole fraction of target species for reaction j, 𝑘𝑗 is the rate coefficient 
for reaction j, 𝑁𝑛 is the total neutral number density, and 𝑛𝑒 is electron density.  
 
Electron energy loss 𝑅ε is defined as: 
𝑅ε = ∑ 𝑥𝑗𝑘𝑗𝑁𝑛𝑛𝜀
𝑀
𝑗=1
∆𝜀𝑗   (𝐸𝑞.  5) 
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where 𝑥𝑗 is mole fraction of the target species for reaction j, 𝑘𝑗 is the rate coefficient 
for reaction j, 𝑁𝑛  is the total neutral number density, and 𝑛𝜀  is mean electron 
energy, ∆𝜀𝑗 is the energy loss from reaction j. The rate coefficients were found in 
literature (see 4.2.3). 
 
For each non-electron species k, mass fraction 𝑤𝑘  is solved from:  
𝜌
𝜕(𝑤𝑘)
𝜕𝑡
+ 𝜌(𝑢 ⋅ 𝛻)𝑤𝑘 = 𝛻 ⋅ 𝑗𝑘 + 𝑅𝑘    (𝐸𝑞.  6) 
where 𝑤𝑘  is mass fraction for species k , 𝑢 is mass average velocity field, 𝑗𝑘  is 
diffusive flux vector, and 𝑅𝑘  is the rate expression for species k. 
 
Electrostatic field 𝑉 is solved from: 
– 𝛻 ⋅ 𝜀0 𝜀𝑟  𝛻𝑉 = 𝜌   (𝐸𝑞.  7) 
where 𝜀0 is vacuum permittivity, 𝜀𝑟is relative permittivity, and 𝜌 is space charge 
density. 
 
Space charge density 𝜌 is solved from: 
𝜌 = 𝑞 (∑ 𝑧𝑘𝑛𝑘 − 𝑛𝑒
𝑁
𝑘=1
)   (𝐸𝑞.  8) 
where 𝜌  is space charge density, 𝑧𝑘  is charge of species k, and 𝑛𝑒  is electron 
density. 
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4.2.2 Boundary Conditions and Initial Conditions 
Surface charge accumulation is applied to the dielectric barrier that is next to the 
grounded electrode,: 
𝑛 ⋅ (𝐷1– 𝐷2) = 𝜌𝑠      (𝐸𝑞.  9) 
where 𝐷𝑘 is diffusion coefficient, 𝜌𝑠 is surface charge density. 
𝜌𝑠 is solved from following equation on the surfaces: 
𝑑𝜌𝑠
𝑑𝑡
= 𝑛 ⋅ 𝐽𝑖 + 𝑛 ⋅ 𝐽𝑒    (𝐸𝑞.  10) 
where 𝑛 ⋅ 𝐽𝑖 is the normal component of the total ion current density at the wall, and 
𝑛 ⋅ 𝐽𝑒 is the normal component of the total electron current density at the wall. 
 
The discharge is driven by a sinusoidal electric potential applied to the exterior 
boundary of one of the dielectric tube: 
𝑉 = 0.5𝑉0𝑠𝑖𝑛(𝜔𝑡)   (𝐸𝑞.  11) 
𝜔 = 2𝜋𝑓 (𝐸𝑞.  12) 
where 𝑉0 is the applied peak-peak voltage 𝑉0, 𝑓 is the voltage frequency, and ω is 
the angular frequency that equals 2πf. 
 
The exterior boundary of the other dielectric barrier is partially grounded. The 
relative permittivity of borosilicate shell was set to be 4.8. The initial number 
neutral species and electrons were set to be 108 and 109 respectively to mimic an 
insulated environment. The densities of neutral species of helium, argon, and 
oxygen molecules are fixed at the initial values given by the fraction at the 
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atmospheric pressure. The gas temperature was fixed at room temperature, 300 K, 
as the gas heating due to the collisions among species was trivial as observed in 
experiments. 
 
4.2.3 Plasma Reactions 
This He/O2 DBD plasma model employs 14 species including electrons 𝑒, helium 
atoms 𝐻𝑒, helium ions 𝐻𝑒+, excited helium atoms 𝐻𝑒∗, helium dimer ions 𝐻𝑒2
+, 
excited helium dimers 𝐻𝑒2
∗, ground-state oxygen atoms 𝑂( 𝑃3 ), positive oxygen 
ions 𝑂+ , negative oxygen ions 𝑂− , positive oxygen molecule ions 𝑂2
+ , excited 
oxygen atoms 𝑂( 𝐷1 ), oxygen molecules 𝑂2, excited oxygen molecules 𝑂2
∗( ∆𝑔
1 ), 
and ozone 𝑂3. Table 5, 𝑇𝑒 and 𝑇 are expressed in volts and Kelvins, respectively; 
𝑂( 𝑃3 ), 𝑂( 𝐷1 ), 𝑂2
∗( ∆𝑔
1 ) are indicated by 𝑂, 𝑂∗, 𝑂2
∗, respectively. A total of 49 
reactions were considered in this model (Table 5). 
 
Table 5. Chemical reactions assumed in He/O2 mixture. 
No. Chemical Reaction Rate Constant (cm3∙s-1) 
--- Helium Reaction (HR) --- 
HR1 𝑒 + 𝐻𝑒 → 𝐻𝑒∗ + 𝑒 4.2𝐸−9𝑇𝑒
0.31𝑒
−
19.8
𝑇𝑒  
HR2 𝑒 + 𝐻𝑒∗ → 𝐻𝑒 + 𝑒 2𝐸−10 
HR3 𝑒 + 𝐻𝑒 → 𝐻𝑒+ + 2𝑒 1.5𝐸−9𝑇𝑒
0.68𝑒
−
24.6
𝑇𝑒  
HR4 𝑒 + 𝐻𝑒∗ → 𝐻𝑒+ + 2𝑒 1.28𝐸−7𝑇𝑒
0.6𝑒
−
4.78
𝑇𝑒  
HR5 𝑒 + 𝐻𝑒2
∗ → 𝐻𝑒2
+ + 𝑒 9.75𝐸−10𝑇𝑒
0.71𝑒
−
3.4
𝑇𝑒  
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HR6 𝑒 + 𝐻𝑒2
+ → 𝐻𝑒∗ + 𝑒 5𝐸−9𝑇𝑒
−0.5 
HR7 𝑒 + 𝐻𝑒2
+ → 2𝐻𝑒 1𝐸−8 
HR8 𝑒 + 𝐻𝑒2
+ + 𝐻𝑒 → 3𝐻𝑒 2𝐸−27 
HR9 2𝑒 + 𝐻𝑒2
+ → 2𝐻𝑒 + 𝑒 5𝐸−27𝑇𝑒
−4.5 
HR10 2𝐻𝑒∗ → 𝐻𝑒+ + 𝐻𝑒 + 𝑒 2.7𝐸−10 
HR11 𝐻𝑒∗ + 2𝐻𝑒 → 𝐻𝑒2
∗ + 𝐻𝑒 1.3𝐸−33 
HR12 𝐻𝑒+ + 2𝐻𝑒 → 𝐻𝑒2
+ + 𝐻𝑒 1𝐸−31 
--- Oxygen Reaction (OR) --- 
OR1 𝑒 + 𝑂2 → 𝑂2 + 𝑒 4.7𝐸
−8𝑇𝑒
0.5 
OR2 𝑒 + 𝑂2 → 𝑂2
∗ + 𝑒 1.7𝐸−9𝑒
−
3.1
𝑇𝑒  
OR3 𝑒 + 𝑂2
∗ → 𝑂2 + 𝑒 5.6𝐸−9𝑒
−
2.2
𝑇𝑒  
OR4 𝑒 + 𝑂2 → 𝑂 + 𝑂
∗ + 𝑒 5.0𝐸−8𝑒
−
8.4
𝑇𝑒  
OR5 𝑒 + 𝑂 → 𝑂∗ + 𝑒 4.2𝐸−9𝑒
−
2.25
𝑇𝑒  
OR6 𝑒 + 𝑂∗ → 𝑂 + 𝑒 8𝐸 − 9 
OR7 𝑒 + 𝑂∗ → 𝑂+ + 2𝑒 9𝐸−9𝑇𝑒
0.7𝑒
−
11.6
𝑇𝑒  
OR8 𝑒 + 𝑂2 → 𝑂
− + 𝑂 8.8𝐸−11𝑒
−
4.4
𝑇𝑒  
OR9 𝑒 + 𝑂2 → 2𝑂 + 𝑒 4.2𝐸−9𝑒
−
5.6
𝑇𝑒  
OR10 𝑒 + 𝑂2 → 𝑂2
+ + 2𝑒 9𝐸−10𝑇𝑒
0.5𝑒
−
12.6
𝑇𝑒  
OR11 𝑒 + 𝑂− → 𝑂 + 2𝑒 2𝐸−7𝑒
−
5.5
𝑇𝑒  
OR12 𝑒 + 𝑂2
+ → 2𝑂 2.2𝐸−8𝑇𝑒
−0.5 
OR13 𝑒 + 𝑂2 → 𝑂
− + 𝑂+ + 𝑒 7.1𝐸−11𝑇𝑒
0.5𝑒
−
17
𝑇𝑒  
OR14 𝑒 + 𝑂2 → 𝑂 + 𝑂
+ + 2𝑒 5.3𝐸−10𝑇𝑒
0.9𝑒
−
20
𝑇𝑒  
OR15 𝑒 + 𝑂 → 𝑂+ + 2𝑒 9𝐸−9𝑇𝑒
0.7𝑒
−
13.6
𝑇𝑒  
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OR16 𝑒 + 𝑂3 → 𝑂2
− + 𝑂 1𝐸−9 
OR17 𝑂− + 𝑂2
+ → 𝑂 + 𝑂2  2𝐸−7 (
200
𝑇
)
0.5
 
OR18 𝑂− + 𝑂 → 𝑂2 + 𝑒 5𝐸
−10 
OR19 𝑂− + 𝑂2
+ → 3𝑂 1𝐸−7 
OR20 𝑂− + 𝑂+ → 2𝑂 2𝐸−7 (
300
𝑇
)
0.5
 
OR21 𝑂+ + 𝑂2 → 𝑂 + 𝑂2
+ 2𝐸−11 (
300
𝑇
)
0.5
 
OR22 𝑂2
∗ + 𝑂2 → 2𝑂2  2.2𝐸
−18 (
300
𝑇
) 0.8 
OR23 𝑂2
∗ + 𝑂 → 𝑂 + 𝑂2  7𝐸
−16 
OR24 𝑂∗ + 𝑂 → 2𝑂 8𝐸−12 
OR25 𝑂∗ + 𝑂2 → 𝑂 + 𝑂2 7𝐸−12𝑒
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𝑇  
OR26 𝑂∗ + 𝑂2 → 𝑂 + 𝑂2
∗ 1𝐸−12 
OR27 𝑂− + 𝑂2 → 𝑂3 + 𝑒 5𝐸
−15 
OR28 𝑂− + 𝑂2
∗ → 𝑂3 + 𝑒 3𝐸
−10 
OR29 𝑂− + 𝑂2
∗ → 𝑂2
− + 𝑂 1𝐸−10 
OR30 𝑂3 + 𝑂2 → 2𝑂2 + 𝑂 7.3𝐸−10𝑒−
11400
𝑇  
OR31 𝑂3 + 𝑂 → 2𝑂2  1.8𝐸−11𝑒−
2300
𝑇  
OR32 2𝑂 + 𝑂2 → 2𝑂2  2.5𝐸
−31𝑇−0.63 
OR33 𝑂 + 2𝑂2 → 𝑂3 + 𝑂2 6.9𝐸−34 (
300
𝑇
)
1.25
 
OR34 𝑂2
∗ + 𝑂3 → 2𝑂2 + 𝑂 6.0𝐸−11𝑒−
2853
𝑇   
--- Helium-Oxygen Reaction (HOR) --- 
HOR1 𝑒 + 𝑂2 + 𝐻𝑒 → 𝑂2
− + 𝐻𝑒 1𝐸−31 
HOR2 2𝑂 + 𝐻𝑒 → 𝑂2 + 𝐻𝑒 1.3𝐸
−33 (
3000
𝑇
) 𝑒−
170
𝑇  
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HOR3 𝑂2
∗ + 𝐻𝑒 → 𝑂2 + 𝐻𝑒 8𝐸
−21 
 
4.3 Plasma Structure 
The plasma model is solved for applied voltage of 4kV and 6kV, and for 
helium/oxygen (1%) flows of 400 and 600 sccm, until the average power deposited 
reaches a steady state (t ∼ 8 µs) corresponding to convergence in reactive neutral 
species production. A basic stationary laminar flow model was first solved to 
provide live pressure and velocity field; it was then coupled with a time-dependent 
plasma discharge model. The outputs results such as the steady-state solution for 
charged particle density, electron temperature and electric field have been 
calculated with the use of COMSOL. A He/O2 plasma discharge with density∼ 1019 
cm−3 forms around the inner electrode tip, but this rapidly decreases to ∼ 1016 cm−3 
in the downstream region. A thin sheath structure is formed extending from the 
electrode tip along the sides (Figure 25). As shown in Figure 26, the electron 
density reaches a maximum value of 2.59×1011 m−3 at about 0.06 m from the 
cathode. The results were generally in line with similar studies reported in other 
journals [175], [176]. In the results discussed here, the densities of oxygen atom 
(O) reached a steady state over a few ms (Figure 27). The extent of surface 
functionalization was investigated as a function of oxygen number density (Figure 
28). 
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Figure 25. Solved He* number density in comparison with photograph 
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Figure 26. Electron density distribution in plasma jet at 50 ns, 100 ns, and 1 µs (top to bottom). 
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Figure 27. Average oxygen atom (O) density at tip of plasma jet. 
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4.4 Orthogonal Experiment Analysis 
An orthogonal experimental design and analysis method was applied to study the 
effects of some parameters not included in, or derived from the kinetics model for 
DBD microplasma treatment of PCL. In this trial case, three DBD plasma system 
parameters involved in , namely nozzle moving speed (v), distance from nozzle tip 
to substrate (d), and average oxygen number density at scale of 1012 (o) were 
investigated.  
 
  
 
Figure 28. Average oxygen atom and ozone number density under different flow rate (Qin), 
peak-peak voltage (Vrc), and power frequency (freq). 
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Table 6. System parameters with contact angle results. 
  
v (z1), 
mm/s 
d (z2), 
mm 
o (z3), 
1012 
Contact 
Angle, ° 
1 1 1 6 55.954 
2 1 3 9 57.377 
3 1 5 12 58.429 
4 3 1 12 57.382 
5 3 3 6 57.387 
6 3 5 9 67.769 
7 5 1 9 67.067 
8 5 3 12 68.196 
9 5 5 6 73.042 
Control       79.589 
 
 
Table 7. A 3x3 orthogonal experimental design plan. 
Investigated parameters v (z1), mm/s d (z2), mm o(z3), 1012 
Zero level: 0 3 3 9 
High level: +1 5 5 12 
Lower level: -1 1 1 6 
Level space 2 2 3 
 
To calculate the regression coefficients of normalized parameters, the original 
states were normalized to generate new variables, varying within the range of [-1, 
1]. The following equation set including zero levels and level spaces was used in 
data processing: 
𝑋1(𝑧1) =
𝑧1 − 𝑧1̅
∆1
=
𝑧1 − 3
2
 (𝐸𝑞.  13) 
𝑋1(𝑧2) =
𝑧2 − 𝑧2̅
∆2
=
𝑧2 − 3
2
 (𝐸𝑞.  14) 
𝑋1(𝑧3) =
𝑧3 − 𝑧3̅
∆3
=
𝑧3 − 9
3
 (𝐸𝑞.  15) 
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𝑋2(𝑧1) = 2 [(
𝑧1 − 3
2
 )
2
−
2
3
] (𝐸𝑞.  16) 
𝑋2(𝑧2) = 2 [(
𝑧2 − 3
2
 )
2
−
2
3
] (𝐸𝑞.  17) 
𝑋2(𝑧3) = 2 [(
𝑧3 − 9
3
 )
2
−
2
3
] (𝐸𝑞.  18) 
 
X1, X2 are first and second order of normalized system parameters respectively. 
The rest of the regression coefficients D, B and b can be calculated as follows: 
𝐷𝑚𝑘 = ∑ (𝑋𝑚
2(𝑧𝑘))
𝑖
9
𝑖=1
 (𝐸𝑞.  19) 
𝐵𝑚𝑘 = ∑(𝑋𝑚(𝑧𝑘) ∙ 𝑦)𝑖
9
𝑖=1
 (𝐸𝑞.  20) 
𝑏𝑚𝑘 = 𝐵𝑚𝑘 𝐷𝑚𝑘⁄ (𝐸𝑞.  21) 
 
Table 8. Calculation results of coefficients. 
 Φ X1 (z1) X2 (z1) X1 (z2) X2 (z2) X1 (z3) X2 (z3) y 
1 1 -1 1 -1 1 -1 1 55.954 
2 1 -1 1 0 -2 0 -2 57.377 
3 1 -1 1 1 1 1 1 58.429 
4 1 0 -2 -1 1 1 1 57.382 
5 1 0 -2 0 -2 -1 1 57.387 
6 1 0 -2 1 1 0 -2 67.769 
7 1 1 1 -1 1 0 -2 67.067 
8 1 1 1 0 -2 1 1 68.196 
9 1 1 1 1 1 -1 1 73.042 
D 9 6 18 6 18 6 18  
Bj 562.603 36.545 14.989 18.837 13.723 -2.376 -14.036  
bj 62.511 6.091 0.833 3.140 0.762 -0.396 -0.780  
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Y is the test results of water contact angles from labeled experiments previously, 
while m and k are the operational parameters in the array. The quantitative model 
between the water contact angle results and given system parameters can be 
expressed as: 
𝑦∗ = ∑ ∑ 𝑏𝑚𝑘𝑋𝑚(𝑧𝑘)
2
𝑚=1
3
𝑘=1
 (𝐸𝑞.  22) 
 
The calculated expression is as follows: 
𝜃 = 62.511 + 6.091𝑋1(𝑧1) + 0.833𝑋2(𝑧1) + 3.140𝑋1(𝑧2) + 0.762𝑋2(𝑧2)
− 0.396𝑋1(𝑧3) − 0.780𝑋2(𝑧3) (𝐸𝑞.  23) 
 
After simplification using the relations from the first set of equations: 
𝜃 = 0.4165𝑣2 + 0.5465𝑣 + 0.3810𝑑2 − 0.6880𝑑 − 0.1733𝑜2 + 2.9880𝑜
+ 41.9033 (𝐸𝑞.  24) 
 
Equation 24 unified average oxygen number density, which is derived from the 
previous computational model, as well as the nozzle moving speed and distance 
from nozzle tip to substrate, which only exist in the dynamic treatment mode of 
localized microplasma process. Errors of computed contact angles are within 5% 
when compared to experimental results. 
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CHAPTER 5: DEVELOPMENT OF A CANCER CELL-ON-A-CHIP 
DEVICE WITH LOCALIZED MICROPLASMA SURFACE 
FUNCTIONALIZATION 
One part of this work appeared in [1] and was done in collaboration with Zhenyu 
Tang, Yu Zhao, Rui Yao, Lingsong Li, and Wei Sun. 
Another part of this work appeared in [177] and was done in collaboration with 
Qudus Hamid, Jessica Snyder, Shannon Williams, Yigong Liu, and Wei Sun. 
5.1 Cell Printing for Cancer Models 
Cell printing is based on bio-additive manufacturing technology, directly 
assembly cells with delivery medium to build 3D tissue constructs layer by layer 
[178]. This approach allows the assembly of heterogeneous tissue structure to 
mimic in vivo physiological tumor model, as well as the possibility of fabricating 
3D in vitro tumor model with large-scale, high throughput and high cell density. 
Cell printing has provided a promising biofabrication technique to produce reliable 
3D in vitro models. Pepper et al. designed a 2D inkjet system to deposit multiple 
cell types like murine mammary tumor cells (4T07) and murine mesenchymal stem 
cells (D1) in predefined patterns, powered by HP26 series print cartridge [179]. 
From 2D to 3D cell printing, Moon, S. developed a layer by layer 3D tissue droplet 
bioprinter to print bladder smooth muscle cells encapsulated within high viscosity 
collagen [180]. Xu et al. printed a 3D co-culture cancer model by a dual ejector 
setup with ovarian cancer cells (OVCAR-5) and fibroblasts (MRC-5) to a Matrigel 
substrate. Acini formation and cell viability were tested but no results about 
functional characterization of the cancer model were gained [181]. Kessel et al. 
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applied ejection technical to eject OVCAR-5 and MRC-5 cells separately and 
formed 3D co-culture cancer models for studying breast cancer initiation and 
progression [182]. These cancer models were used as quantitative therapeutic 
response platforms for ovarian cancer (OvCa) micrometastases, through which they 
demonstrated that BPD-PDT treatment of OvCa 3D micronodules substantially 
improves the efficacy of a clinically relevant dose [182].  
 
Matsusaki et al. combined the rapid and automatic inkjet cell printing to 
fabricate micro-arrays of simplified human 3D-tissue structures with different 
cellular distributions [183]. This work reported hundreds of multilayered micro-
tissues integrated into one micro-array and declared to reproduce 3D cell-cell 
interactions similar to actual tissue. Although HepG2 cells and HUVEC were co-
cultured in chips, the cancer biological properties were not assessed in this work. 
Laura developed a micropatterned system using sequential microcontact printing 
of hyaluronic acid (HA) with ECM protein fibronectin [184]. Breast cancer cells 
laden HA micromolded hydrogels were spatially organized using this system, and 
analysis of the spatial and temporal mechanisms regulating tumor angiogenesis was 
declared to be available with this method. Zhao reported a controlled cell assembly 
for 3D tumor model using printing method with gelatin, alginate and Hela cells 
[185]. The Hela cells were successfully assembled to a construct and about 80% 
cells were alive after cell assembly, according to staining analysis. This 
demonstrated tumor cell assembly with the advantage of mimic ECM, large-scale 
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and high throughput had potential to build a biomimetic tumor model with 3D 
microenvironmental characteristics in vivo [185]. 
 
5.2 Development of a Multifunctional Biofabrication System 
The integrated multifunctional cell printing system integrates several 
critical fabrication components utilized in the fabrication process of many 
biological arrays and platforms. These components include: 3D spatial control, 
material deposition, the ability to perform photolithographic processes, and plasma 
treatment systems. The 3D spatial control houses all the fabrication components on 
the z motion arm with connectivity to an x and y arm for complete 3D motion. The 
material deposition component houses the biological nozzle and the photo-polymer 
nozzle. The biologics head is a cell-friendly deposition nozzle on the motion arm 
that is used for the spatial deposition and orientation of cells and/or biologics into 
the micro-channels. The ﬁnal nozzle of the material delivery component is a piston 
style nozzle which is used to drive material of higher viscosity, such as photo-
polymers. The photolithographic head has a LED ultra-violet (UV) ﬁber optic head 
that is mounted on the motion arm. Photolithographic component is used for the 
crosslinking of the photoresist immediately after deposition. Prior to cell deposition, 
the plasma treatment head will treat the channels with a composition of helium and 
oxygen based plasma.  
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The 3D spatial control component is integrated with all the components (UV, 
plasma, and material delivery nozzles) and functions independent of each 
component. Each component of this proposed system has a speciﬁc function; if a 
function or component is not needed, the scripts (program code) can be written to 
function as desired. All nozzles/print head are independent of each other and only 
one head is utilized at a single time. All print heads are housed on the third (Z- axis) 
motion arms. All nozzles utilize the spatial controllers in sequential order to 
develop and enhance the fabricated arrays while depositing biologics into the 
channels. The motion system is controlled by a proportional—integral—derivative  
controller,  that allows for tuning of the entire system to function adequately with 
any given fabrication task.  
 
Photosensitive polymer such as SU-8 requires direct exposure to UV light 
for the development of microchannels. The freeform UV micro-nozzle has a base 
LED UV lamp where a ﬁber optic cable is fed to the motion head. The ﬁber optic 
 
Figure 29. (A) An image of the integrated fabrication system; (B) close-up of the four fabrication 
heads respectively labeled. 
A B
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cable is placed into the print head which is speciﬁcally designed to ﬁlter the light 
through an inter-changeable micro-nozzle. This component emits a peak UV light 
of 485 nm through 50–500 μm nozzles with a manufacturer’s list maximum 
exposure of 15 W cm-2. The freeform UV micro-nozzle is coupled with the photo-
polymer head which allows for immediate crosslinking of the photo-resist upon 
deposition.  
 
The photo-polymer head is speciﬁcally designed to work with high viscous 
material. Due to space limitations, the piston style design of this head enables the 
author to drive a small amount of material without requiring a lot of room. This 
head features a syringe–pump style deposition system that utilizes standard 
syringes with inter-changeable nozzles. The utilization of standard everyday 
products allows the end-users to work effectively with tissue culture products. The 
head is controlled with an Audrino micro-processor which is embedded into the 
motion software. The photo-polymer head is coupled with the freeform UV micro- 
nozzle. This placement allows for immediate cross- linking of the photo-resist upon 
deposition which retains structural integrity. Figure 3(B) shows an image of the 
photo-polymer head with its major components. 
 
The biologics component is inspired by rapid proto-typing technology and 
is built on a CAD/CAM plat- form, which integrates with the 3D spatial control 
component. The biologics printer operates at room temperature and low pressure, 
necessary cell-friendly conditions. Coupled with the spatial control component, the 
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biologics printer can deposit multiple cell types and bioactive factors in controlled 
amounts with precise spatial positioning. The printer utilizes a micro-valve nozzle 
which enables the printer to deposit numerous solutions with a wide range of 
material and biological properties. This component eliminates human errors and 
provides the end users with precise biologics control during fabrication procedures. 
The biologics deposition component is capable of depositing heterogeneous 
materials, cell types, and biological factors in a controlled and reproducible manner 
[53–55]. Cell printing is considered to be an effective biofabrication tool to 
assemble biologics and will be used as such in this chapter.  
 
The generation of plasma is done by changing the gas types, ﬂow 
composition, and applied electric ﬁeld within the nozzle along with the 
corresponding process parameter for generating the desired ignition. Plasma 
generation is the excitation of ions that bombard the substrate’s surface to 
manipulate its topology, surface chemistry and functional groups. In this system, 
the micro-plasma is delivered through the dielectric barrier discharge (DBD) 
technique. DBDs are non-equilibrium plasmas operated under atmospheric 
pressure [168]. Due to a non-equilibrium nature, DBD plasmas can generate high 
energy electrons at cool background gas temperatures (heavy particles). This 
unique character (selective high electron temperature, and low background 
temperature) enables rich plasma chemistry in many plasma chemical processes 
[166]. The micro-plasma component consists of a power supply and the plasma 
electrode components. Micro-plasma will be generated by a pulsed power supply 
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with variable frequency. Connected to the power supply will be the plasma 
electrode system with a high voltage electrode coaxially inserted in a dielectric 
(borosilicate glass or quartz) tube and a ground electrode wrapped around the tube 
from the outside. The process gas (or gas mixture) will be purged through the 
annular gap between the coaxial electrode and the dielectric tube. When the high 
voltage electrode is powered, plasma ignites between the electrodes and a micron-
scale glow-like plasma will appear at the tip of the nozzle. Once the micro-plasma 
contacts the surface of biopolymer, it will change the topography and chemistry of 
the plasma-exposed area. Depending on the micro-plasma operation parameters 
such as plasma power, gas ﬂow rate, gas composition, and nozzle tip diameter, the 
users can control the surface chemistry and topological features of the exposed 
photo-polymer.  
 
5.3 Fabrication of a Cancer Cell-on-a-chip Device 
Limited nutrient and metabolic waste transport is an essential concern in 
spheroid constructs due to a large and dense ECM structure. Therefore, a call for 
microfluidic systems, which are known for compact size and accurate flow control, 
to be applied in in vitro cancer models is reasonable. Soft photolithography is the 
typical method to fabricate mold of the lab-on-chip device and 
Polydimethylsiloxane (PDMS) is widely used during the manufacturing process, 
for its biocompatibility and oxygen permeability. The PDMS molds are covered by 
glass coverslip with the edges fully sealed which allows microscopic observation 
of cells and tissues without involving exterior contamination [186].  
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Recent work focused on the combination of microfluidics and cell culture 
systems to improve the physiological significance and the reproducibility of cell-
based assays [187]. A transparent microchannel array enables observation of spatial 
and temporal controls on the transition of breast cancer invasion [188]. The design 
of channels in a microfluidic device is often crucial to regulate cell behaviors, 
further to mimic tumor development and metastasis. Hsiao et al. developed a two-
layer microfluidic system to co-culture spheroids of metastatic prostate cancer cells 
(PC-3), osteoblasts and endothelial cells; all of the cells were fluorescently labeled 
for separation, imaging and tracking. Their results demonstrated a large decrease in 
the proliferation rate of PC-3 cells with maintained viability, which recapitulate the 
growth behavior of malignant cancer cells within native in vivo microenvironment 
[82]. Moreover, Zervantonakis et al. engineered a microfluidic assay to reconstruct 
the 3D ECM of tumor-vascular interface; the results showed that the endothelium 
stalled tumor cell intravasation via microenvironment factors [189]. Generally, 
microfluidic system allows for analysis of cell kinetics and diffusion effects in 
growing cell populations which is distinctive among all models. 
 
The cell-on-a-chip presented in this chapter was fabricated in two parts. The 
ﬁrst part of the chip is referred to as the enclosure and the second part of the chip 
is the fabrication of the internal architecture. The enclosure is fabricated with an 
aluminum mold which produces a base enclosure and a lid. The base enclosure has 
a rectangular slot that is later utilized by the fabrication system to print, treat, and 
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deposit cells in the desired micro-architecture. The lid is ﬂat and houses the inlet 
and outlet ports which are utilized for perfusion throughout the chips during the 
incubation period. The enclosure is made primarily out of polydimethylsiloxane 
(PDMS) (Dow Corning, Michigan, USA) and the inlet and outlet ports are nylon 
based luer-lock connectors (McMaster-Carr, Robbinsville, NJ, USA). PDMS is 
mixed at a 1:15 ratio, de-gassed and cured in an aluminum mold at 130 °C for 10 
min. Cured PDMS is cooled and removed from the aluminum mold. This process 
is repeated for the lid where the luer-lock ports are placed into position prior to 
being cured on the hot plate. Figure 30(B) illustrates a model of the PDMS 
enclosure. Prior to the fabrication of the internal features of the chip, the enclosure 
goes through a dry heat sterilization process of 150 °C for 2 h. 
 
The second part of the chip is the fabrication of the internal architecture 
which sits in the slot of the base enclosure. The internal micro-architecture of the 
chip is fabricated with the integrated system using SU-8 2100 (MicroChem Corp., 
Newton, MA, USA) as the building material. SU-8 is housed in the photo- polymer 
print head. The localized micro-plasma head uses a gas composition of 5% oxygen 
and 95% helium for plasma treatment [59, 60]. Cells used in studies presented in 
this chapter are MDA-MB-231 (breast cancer cells) and HepG2 (liver cancer cells) 
(American Type Culture Collection, Virginia, USA). Prior to printing, cells are 
harvested from a 75 cm2 tissue culture ﬂask and counted then re-suspended at a cell 
density of 1 × 106 cells/ml (50% MDA-MB-231, 50% HepG2) in culture medium 
(50/50, MDA-MB-231 culture medium/HepG2 culture medium) and placed in the 
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biologics head. The freeform UV micro-nozzle is set at 100% intensity with a 500 
μm nozzle. 
 
The fabrication of the internal architecture is done in a sequential series of 
steps: 
Step 1: The ﬁrst step is the photo-polymer head moving into the slot of the 
enclosure base, then depositing the SU-8 forming a line ﬁlament height of 0.5 mm. 
Step 2: Once the ﬁrst ﬁlament is printed, the UV head activates and follow 
the same toolpath and exposes the printed SU-8. This process is repeated until the 
desired ‘layer’ is printed and exposed (UV). The fabrication method utilized by this 
3D printer is layer-by-layer fabrication. 
Step 3: (Optional): Since the chip has only one layer, the fabrication of a 
second layer would be identical to the ﬁrst (process-wise). 
Step 4: Once the microchannels have been created, the plasma head will 
activate and move over the path of the printed microchannels, treating them. 
Step 5: Once the plasma treatment is completed, the biologics head will 
follow the path of the micro- channels and print cells directly into channels. 
Step 6: To seal the chip, the plasma head will activate once more and treat 
the PDMS on the enclosure. The plasma treatment allows for a seal on PDMS–
PDMS contact between the lid and the base of the enclosure. 
Step 7: After treatment, the lid is placed onto the base enclosure then 
incubated. 
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Figure 30(A) is schematic illustrating the fabrication steps of developing 
the cell-on-a-chip device. Figure 30(C) shows an image of the fabricated 
microchannels within the slot of the PDMS enclosure and Figure 30(D) shows an 
image of the completed cell- laden microﬂuidic chip with the lid and its inlet and 
outlet ports. Figure 31 presents a ﬂow chart illustrating the fabrication processes of 
the integrated system to develop a biological microﬂuidic chip. 
 
 
 
 
Figure 30. (A) A schematic illustrating the fabrication steps of developing the cell-laden 
microﬂuidic chip, (B) a model of the PDMS enclosure, (C) an image of the fabricated 
microchannels within the slot of the PDMS enclosure, (D) an image of the completed cell-laden 
microﬂuidic chip with the lid and its inlet and outlet ports. 
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Figure 31. Flow chart illustrating the fabrication process of a biological microﬂuidic chip using the 
integrative fabrication process. 
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5.3.1 Internal Architecture Validation 
The morphology of the cells within the microchannels was visualized by 
confocal microscopy and scanning electron microscopy (SEM). Cell morphology 
and the internal micro-architecture were evaluated using an FEI/Philips XL-30 ﬁeld 
emission environmental scanning electron microscope. The images obtained from 
the SEM were taken using a beam intensity of 2 kV and gaseous secondary electron 
detectors of 1.3 Torr. Prior to SEM investigation of the micro-architecture and cell 
morphology, the lid of the chips was sectioned using a sharp straight razor. After 
sectioning, the chip was then prepared by ﬁrst ﬁxing the cells in 2% glutaraldehyde 
for 2 h followed by a dehydration process of submerging the sample in 50%, 60%, 
70%, 80%, 90%, and 100% ethanol in series for 10 min. Samples were stored in a 
4 °C refrigerator overnight, then splutter-coated with platinum (approximately 10 
nm thick) for visualization. All biological investigation data are expressed as the 
mean ± standard deviation for sample size of 4 (n = 4). 
 
Utilizing the above process parameters with a 250 μm nozzle on the 
biologics head and a 500 μm nozzle on the photo-polymer head, UV head, and 
plasma head; a sinusoidal microfluidic chip with a channel width and height of 500 
μm each was fabricated. Since the biologics head prints inside of the microchannels, 
the nozzle diameter has to be smaller than the width of the channel. The 250 μm 
nozzle allowed for spatial control of the printed cells inside of the 500 μm 
microchannels. To check for structural integrity of the fabricated microchannels, 
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and SEM characterization was conducted after the SU-8 was exposed with the UV 
head. Figure 32 shows the results of this investigation. Figure 32(A) shows the 
uniformity of the channels while Figure 32(B) shows the end of the microchannel 
in which the direction changes from a horizontal channel to a vertical channel then 
back to a horizontal channel. Both SEM images prove that the chip is of the 
specified dimensions. 
 
 
5.4 Cell Integration, Attachment, Proliferation, and Tracking 
Cells are labeled with Qtracker® cell labeling kit to track cells in co-cultures 
within the microﬂuidics. Qtracker® cell labeling kits are designed for loading cells 
grown in cultures with highly ﬂuorescent Qdot® nanocrystals. Once inside the cells, 
Qtracker® labels provide intense, stable ﬂuorescence that can be traced through 
several generations, and are not transferred to adjacent cells in a population. 
Qtracker® 525 and 625 are used to label the HepG2 and MDA-MB-231 cell lines, 
respectively. Qtracker® 525 emission is 525 nm and excitation is 405–485 nm. 
 
Figure 32. (A) SEM image showing the uniformity of the fabricated microchannels, (B) SEM image 
showing the end of the microchannel in which the direction changes from a horizontal channel to 
a vertical channel then back to a horizontal channel. 
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Qtracker® 625 emission is 625 nm and excitation is 405–585 nm. Prior to 
investigation, the working solutions were made by preparing 10 nM labeling 
solution, pre-mix 1 μL each of Qtracker® component A and component B in a 1.5 
mL micro-centrifuge tube. Incubate for 5 min at room temperature then add 0.2 mL 
of fresh complete growth medium to the tube and vortex for 30 s to complete the 
working solution. This protocol was followed for both cell labeling kits for its 
correspond- ing cell type. Prior to the cells being loaded into the biologics head, 
each cell type was suspended in its corresponding cell labeling working solution 
for an incubation period of 45–60 min. After incubation, cells were washed twice 
with complete growth medium then re-suspended and loaded into the biologics 
head for printing. A ﬂuorescence microscope and micro-plate reader (GENios, 
TECAN, North Carolina, USA) were used for characterization. 
 
The Qtracker® kits allowed for tracking each cell type under a ﬂuorescence 
micro- scope and the quantitative characterization of each cell type with the use of 
a microplate reader. Since both cell lines were mixed together and printed into the 
microchannels, it is expected that both cell lines integrate with each other, attach 
and proliferate together. Figure 33(A) is a merged ﬂuorescence image taken 
through a 525 and 625 nm ﬁlter showing the MDA-MB-231 cell line in red and the 
HepG2 cell line in green. This image proves that both cell lines are integrated with 
each other. Figure 33(B) is a phase-contrast image coupled with Figure 33(A) to 
illustrate the cell distribution within the microchannels. Both images were taken at 
day 7 during the investigation. Cell distribution and active proliferation throughout 
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the 21 day study was collected and analyzed and is showed in Figure 33(C). As 
seen in Figure 33(C), both cell types have an even cell distribution throughout the 
chip. Also, over the 21 days, there is an increase in ﬂuorescence intensity which 
demonstrates an up- regulation in cell proliferation for both cell lines. 
 
 
 
5.4.1 Evaluation of Cell Viability and Metabolic Activity 
Cell viability and metabolic activity is investigated to assess the changes in 
function of the cells within the microchannels. The topological and chemical 
modiﬁcation provided by microplasma may induce structural and functional 
changes in cellular function. A ﬂuorometric investigation was conducted with the 
use of AbD SeroTEC’s Alamar Blue (Ab). The cell-on-a-chip devices were washed 
with 1x phosphate buffered saline (PBS) by pumping the PBS through the chips 
 
Figure 33. (A) Fluorescence image showing cell distribution and integration of the MDA-MD-231 
cells (red, Qtracker® 625) and the HepG2 cells (green, Qtracker® 525) within the microchannels, 
(B) a phase-contrast image of the cells in the microchannel, (C) quantitative results of the cell 
distribution of the MDA-MB-231 and HepG2 cell lines within the microﬂuidic chip. 
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with a syringe pump at a ﬂow rate of 30 μLh 1. 10% Ab was mixed with the co-
culture medium and was pumped through the chips at 30 μL/hr until the chips were 
ﬁlled with the reagent. The chips were then disconnected from the syringe pump 
and were placed in the incubator for 4 h. After 4 h, the resulting reagent within the 
chips was removed from the chips and characterized with a microplate reader 
whose excitation and emission wavelengths were 535 and 590 nm respectively. 
 
Ab was used as a secondary proliferation characterization method. This will 
further conﬁrm the results from the Qtracker® kits. This proliferation study 
characterizes the total cell growth within the entire chip but does not differentiate 
between cells. For comparative data, two control chips were investigated where one 
chip was seeded with only MDA-MB-231 cells and the other was seeded with 
HepG2 cells. This study shows the cell proliferation within the chips and 
comparatively shows the effects of co-culturing these two cells in a microﬂuidic 
environment. Figure 34 shows the results of this study. The data shows that over a 
21 day period under the same microﬂuidic environment, the MDA-MB-231 cells 
proliferated the fastest while the HepG2 cells had the slower proliferation rate. The 
chip with both cell lines started with a slow proliferation rate; however, at the end 
of the 21 day study, the co- culture chip had higher ﬂuorescence intensity than the 
chip with the HepG2 cells. This trend demonstrates that when the two cells are 
coupled together, it takes a little longer for them to generate and that the 
environment in which both cell lines are in can thrived in. After about seven days, 
the proliferation trend suggests that the extra-cellular matrix created by both cell 
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lines allowed for an up-regulated cell proliferation trend. The results from the cell 
proliferation and cell tracking/cell integration investigation suggest that the co- 
culturing of two cell lines in a microﬂuidic chip with enhanced surface treatment is 
feasible. 
 
 
 
5.4.2 Cell Morphology 
SEM characterization provides an in-depth look of the cell morphology 
within the microchannels. This characterization allows for visualization of cell 
integration within the microchannels by their morphologies and conﬁrms that cells 
 
Figure 34. Results of the 21 days cell proliferation study of the MDA-MB-231 cell-laden chip 
(control 1), HepG2 (control 2) cell-laden chip, and the co-culture (both MDA-MB-231 and HepG2 
cell lines) cell-laden chip. 
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are integrated and are growing within the channels. Figure 35 shows a set of SEM 
images presenting an overview of the cells within the microchannels (Figure 35(A)), 
a close-up of the integrated cells (Figure 35(B)), and the corresponding 
morphologies of each cell types (Figure 35(C) and (D)). As seen in Figure 35(A) 
there is a uniform distribution of cells throughout the microchannels. This is the 
same throughout the entire chip. This image demonstrates the capabilities of the 
biological deposition component of the integrated system to precisely print cells in 
a controlled pattern. Utilizing the morphologies of the MDA-MB-231 (Figure 
35(C)) and HepG2 (Figure 35(D)) cells lines with the close-up view of the cells in 
the microchannel (Figure 35(B)), it is clear that the two cell lines are indeed 
integrated throughout the chip. 
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Figure 35. (A) SEM image showing an overview of the cell distribution within the microchannel, 
(B) SEM image showing a close-up of the cells within the microchannel, the MDA-MB-231 and 
HepG2 cells are labeled, (C) SEM image showing the morphology of a MDA-MB-231 cell, (D) 
SEM image showing the morphology of a HepG2 cell. 
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5.5 Limitations and other Techniques for Creating Cancer Models 
The fabrication method presented in this chapter is unique and 
advantageous. While it allows for the fabrication of biological microﬂuidics 
without the use of harsh chemicals, it does have some limitations. The fabrication 
process is only utilizing one print head at a time and the microscopic nozzles only 
allow for the development of micro-systems only. This device cannot develop 
systems on the macro scale. It does have the ability to fabricate a series of micro-
structures that can be summed into the macro scale; however, fabricating systems 
such as these can lead to prolonged fabrication time. If the systems are fabricated 
without cells, the lengthy fabrication time is not an issue. However, if the system 
has cells, the lengthy fabrication time will decrease the cell viability. As 
demonstrated in this chapter, the fabrication of one layer does not affect the cell 
viability at the end of the fabrication process. However, the introduction of a second 
layer will decrease the cell viability due to the use of the UV print head. Fabricating 
an additional layer will not lead to the demise of all the cells in the layers below, 
only a small fraction. The localized treatment of the UV print head is speciﬁcally 
developed to minimize cell death during the fabrication process such that the 
fabrication of advanced micro-structure. In addition to fabrication limitations, there 
are characterization limitations. Since the micro-systems are enclosed in PDMS, 
depending on the enclosure thickness and microscopy instrument, it may be 
difﬁcult to qualitative characterize what’s happening inside of the chip. 
Characterization techniques should be considered during the development of 
advanced micro-systems. 
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5.5.1 Spheroids in Suspension 
Cellular spheroids are small tightly bounded cellular spheres with size 
ranged from 20 µm to 1 mm. These cellular aggregates are often obtained through 
the spontaneous tendency by buoyancy or stirring, and exogenous scaffold or 
matrix is usually not needed during the spheroid formation. In breast cancer study, 
researchers showed that human breast carcinoma cell (MDA-MB-435) would 
spontaneously assemble during cell aggregation [190]. Buoyancy was exploited in 
the “hanging-drop” technique: droplets of culture medium containing cells were 
suspended from microtiter plates. After several days of growth, large spheroids 
were obtained. Alternatively, rotational stirrers were employed for spheroids 
formation [191].  
 
Besides hanging drop method, typical methods also include continuous 
agitation of suspension culture in a rotary cell culture vessel or a spinner flask [76], 
[192], culturing on cell repulsive substrates [193], and entrapment within 
biologically inert 3D hydrogel matrices [194]. Spinner ﬂasks are used for culturing 
cells as a dynamic suspension placed in liquid media. Cells deposited in stirred-
tank bioreactors were mixed by impeller to maintain a state of suspension. During 
the formation of spheroids, the gyratory rotation increases the fluid transport of 
both nutrients and waste. This technique is suitable for culturing large populations 
of spheroids under controlled exterior parameters with regard to oxygen, nutrient 
supply, and pH. To grow sensitive cells and form larger spheroid-like structures, 
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microcarrier beads were often used along with gyratory and spinner flasks. NASA 
further developed a rotating-wall vessel to stimulate microgravity which minimizes 
fluid turbulence and shear forces compared to the spinner flask. The fluid shear 
force can be an influential stimulus to certain type of cells, e.g., osteoblasts [195]. 
The low shear environment was a great advantage for mitigating the negative effect 
of fluid turbulence, which was known to damage fragile cells by inducing 
membrane breakage and affecting metabolism [196]. 
 
Spheroids are commonly used in clinical research, especially as models of 
small solid tumors. Pioneer studies on growth of mammalian tumor spheroids dated 
back from 1980s [197], [198]. Since the tumor-stromal interactions in 3D co-culture 
spheroids provide important clues to the behavior of capillaries in tumor, 
multicellular spheroids mixing immortalized cells and various types of stromal cells 
provided better mimicry of natural physiology than monocellular spheroids. The 
symmetrical spherical geometry benefits modeling and analysis of dynamic 
processes, and automation in fabrication of spheroid aggregation. Besides, there 
was no need for bioactive scaffolds, as a result cellular spheroids-based assays have 
a great potential to be scaled up to rapid, high-throughput analysis [6]. These 
limitations includes; the inability to capture the interactions that occur in vivo, for 
example, host immune reactions and angiogenesis; and challenges in controlling 
the size of spheroid [199]. With current advances in microscopy imaging like light 
sheet fluorescence microscopy [200], cellular spheroids regain the importance as 
an in vitro cancer model, especially for preclinical anti-cancer drug screening.  
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5.5.2 Gel Embedding 
Biological gels, which are traditionally used to encapsulate a small tumor 
explant with a gel matrix, are developed as substrate to better mimic in vivo 
microenvironment since they can provide rich network of ECM signals. Contrary 
to some traditional spheroids which lack adhesion to a surface, gels embedded cells 
have both cell-cell and cell-matrix attachments [87]. Gel embedding could help 
promote cancer cell proliferation rate [201], wound tissue expansion, and 
angiogenesis (with fibroblast embedded) [202]. Moreover, it could also change 
cancer cell migration modes with certain in vivo fidelity [203]. 
 
Collagen, alginate and Matrigel are most commonly used gel materials in 
constructing 3D cellular models. Researchers often mix two or three different gels 
to form composite gel matrix to manipulate gel concentration, composition and 
mechanical properties, which would further influence tumor cell attachment and 
migratory capabilities. Comparison of gel embedding protocols was discussed for 
breast cell analysis [204]. Krause et al. developed a co-culture system of human 
epithelial cells and fibroblast cells in type I collagen and Matrigel-collagen matrix, 
respectively, to resemble the mammary gland structures found in vivo. These results 
illustrate the contribution of ﬁbroblasts to the formation of ductal structures [40]. 
Other combination such as a mix of hyaluronic acid derivatives with cells was 
successful in evaluating the efficacy of anti-cancer drugs [77].  
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Additionally, gel embedding method can be associated with microfluidic 
device to create multicellular co-culture system to eliminate the transport 
limitations as seen in traditional spheroid culture. For example, Jeon et al. reported 
a novel microfluidic device consisting of a set of parallel channels separated by an 
array of posts which allow selective ﬁlling (collagen, fibrin, Matrigel) of individual 
channels for co-culture. Macrophage cells (RAW 264.1) were found to permeate 
into neighboring gels containing (MDA-MB-231) metastatic breast cancer cells, 
which demonstrated the potential of gel embedding combined with microfluidic 
technology for 3D cancer model establishment [205]. Still, environmental signals 
like substrate morphology (2D vs 3D) and pH would account for change in cellular 
behaviors [206]. 
 
5.5.3 Scaffold Based Models 
Engineered scaffolds have been employed as a biomaterial-based approach 
for simulating the extracellular matrix and providing physical/structural support. 
These structures constructed from biocompatible synthetic polymers can be used as 
a support matrix for in vitro cell culture as well as in vivo tissue regeneration [207]. 
The application of microfabrication techniques to novel biomaterials provides a 
well-controlled approach to develop functional microvasculature that mimic native 
organ and tissues [79]. Freeform fabrication is a rapid manufacturing technique to 
fabricate 3D porous bioactive scaffolds with complex architectural structures and 
well-defined material properties using Computer-Aided-Design (CAD) models. 
Dhiman et al. constructed a 3D chitosan scaffold and seeded with human breast 
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cancer cell line (MCF-7). Results showed that more lactate and glucose were 
produced from cells grown on chitosan scaffold than cells grown on 2D culture 
plate [38], [39]. Based on previous work, Zhang et al. constructed a 3D chitosan-
alginate (CA) scaffold to promote the conversion of cultured glioma cells to a more 
malignant in vivo-like phenotype, with results indicating that human glioma cells 
(U-87 MG and U-118 MG) showed remarkably higher malignancy when cultured 
in CA scaffolds [208].  
 
Another technique to fabricate porous 3D scaffolds is electrospinning, 
which creates non-woven mats volume as ECM analogue scaffolds. By applying 
high voltage on flowing polymer solution, polarity is increased inside the polymer. 
While polymer solution is extruded from a capillary nozzle, a collector with an 
opposite polarity rotates for polymer deposition. On the fabricated electrospun 
fibers, cells are broadly seeded thanks to a high surface area to volume feature. The 
ﬁbers have micrometer to submicrometer diameters ranging from 100 to 5000 nm 
due to different settings of processing parameters, which include applied voltage, 
flow rate, and capillary-collector distance [209]. One major advantage of 
electrospinning is the cost efficiency for using very small quantities of polymers. 
A second advantage is that additional components such as co-polymers and growth 
factors can be added to the polymer solution in the preparation process and then be 
incorporated into the electrospun ﬁbers [79]. A coaxial nozzle was designed to mix 
the living cells with Poly(ethylene oxide) (PEO) and Glutaraldehyde (GTA) during 
electrospinning process while still maintaining certain cell viability. [210]. This 
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type of scaffold was widely used in drug screening research, thanks to its inherent 
high porosity. A set of nanofiber scaffolds composed of Poly(3-hydroxybutyrate-
co-3-hydroxyvalerate) (PHBV) with collagen peptide, were fabricated to test the 
sensitivity of cancer cells to anticancer drugs, ; as a result, higher concentrations of 
anticancer drugs were required to achieve a comparable cytotoxic effect in 3D 
nanofiber scaffolds [211]. In another study, a 3D electrospun PCL scaffold cultured 
with Ewing sarcoma cells succeeded in reproducing several presumed mechanisms 
of drug resistance, in accordance with the clinical data. Apart from organic 
biopolymers, recent research on organic-inorganic hybrid bioceramics showed that 
growth factors could be strongly grafted to these materials instead of traditional 
coating [212]. This indicates a potential application for cancer scaffold models. 
Therefore the scaffold based models is a valuable tool to investigate anti-cancer 
drug mechanisms. 
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CHAPTER 6: CONCLUSION 
6.1 Research Summary 
This study focus on developing experimental techniques, and computational 
tools that allow for the design surface properties of engineered three-dimensional 
structures to manipulate and control the cellular functions. A novel freeform 
microplasma generated maskless surface patterning process was developed to 
create spatially defined topological and chemical features on biopolymer surface. 
Specifically, in this study, global and localized plasma functionalization were 
applied on polycaprolactone (PCL) samples to introduce biophysical, biochemical, 
biological and structural cues to enhance cellular response including attachment, 
proliferation and differentiation. In addition, a plasma computational-statistical 
model was developed to predict the changes in biopolymer surface 
physicochemical properties following the oxygen based plasma surface 
functionalization. Furthermore, an integrated system including localized plasma 
functionalization is specifically designed for the development of biologically 
inspired cell-on-a-chip devices. The capabilities, benefits, and challenges of the 
integrated multifunctional biofabrication system to develop cell-on-a-chip device 
is also illustrated. 
 
6.2 Research Contributions 
The research contributions are summarized as follows: 
1. The effect of oxygen-based global plasma surface modification of 
polycaprolactone (PCL) samples on cellular functions was investigated 
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as a primer to develop a localized plasma treatment system. This study 
illustrated the manufacturing and oxygen-based plasma modification 
processes of PCL samples. The methods in surface and biological 
characterization of plasma modified PCL sample were described in 
details. Changes in surface physicochemical properties by oxygen-
based plasma modification improved cell-surface interaction.An 
atmospheric-pressure microplasma jet based on dielectric barrier 
discharge (DBD) was integrated to a patented cell printing system which 
allows biologics deposition in the x-y-z directions at various trajectory 
presets. Several characterization and biological studies indicate that the 
localized microplasma treatment improved surface morphology and 
chemistry, caused an increase in hydrophilicity. Improved cell viability 
and proliferation were observed only on selective regions, as compared 
to global plasma treatment. 
2. A novel atmospheric-pressure microplasma jet based on dielectric 
barrier discharge (DBD) was integrated to a patented cell printing 
system. The integrated system allows not only biologics printing but 
also plasma deposition in the x-y-z directions at various trajectory 
presets. Several characterization and biological studies indicate that the 
localized microplasma treatment improved surface morphology and 
chemistry, caused an increase in hydrophilicity, which was in line with 
the results from global plasma treatment studies. Improved cell viability 
and proliferation were observed only on selective regions, as compared 
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to global plasma treatment. This unique system enables researchers to 
produce surface patterning without using costly and hazardous chemical 
masks for cell printing applications. 
3. A two-dimensional (2D) plasma computational-statistical model of the 
atmospheric-pressure microplasma jet was developed to predict surface 
condition after localized plasma treatment using aforementioned system. 
The effect of mass species transport to polymer surface was investigated 
by coupling an incompressible fluid dynamics model to a plasma 
kinetics model. The modeling results involve tracking the different 
physical processes during microplasma discharge, such as discharge 
breakdown, radical chemistry, and surface kinetics. Oxygen production 
rate was computed from this model to link with water contact angle 
changes, and further to predict surface condition with input of different 
system parameters. 
4. Four independent biofabrication techniques were integrated in a novel 
automation system to develop cell-on-a-chip devices. This study also 
illustrated the capabilities, beneﬁts, and challenges of the integrated 
multifunctional biofabrication system. Several biological investigations 
were presented to demonstrate the system’s capabilities to produce 
advance functional cancer cell-on-a-chip device. The novel integrated 
multifunctional fabrication system eliminates the limitations of 
conventional photo-lithography and provides researchers with the 
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capabilities to develop advantageous cell-on-a-chip and organ-on-a-
chip devices on a single platform. 
 
6.3 Future Work 
The localized microplasma surface functionalization system succeeded in 
creating maskless patterns for various cell printing applications. It is also possible 
to generate gradient polymer surfaces by adjusting nozzle moving speed and height, 
contrary to a common method as applying a specially designed mask [213]. 
Preliminary study results showed gradient distribution of water contact angles 
along microplasma treated lines on PCL surfaces. This part of work has been 
presented at International Conference on Biofabrication 2014 in Korea, but an 
intensive study has yet to be conducted. 
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